<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm: Ulcerative Colitis</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest headlines from journals and sites in the Ulcerative Colitis category.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22ulcerative+colitis%22&t=Ulcerative Colitis&f=c&s=Search&r=Any&o=d]]></link>
        <lastBuildDate>Sat, 21 Nov 2009 16:52:24 +0100</lastBuildDate>
        <item>
            <title>[Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases.]</title>
            <link>http://www.medworm.com/index.php?rid=3013229&amp;cid=c_1_25_f&amp;fid=38199&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19921621%26dopt%3DAbstract</link>
            <description>CONCLUSIONS. We report a great variety of etiologies and patterns of presentation of CVT. CVT should be suspected in patients with subacute headache, even in outpatients. Nonacute presentation with isolated headache or intracranial hypertension could have better prognosis, requiring a less aggressive therapy.
    PMID: 19921621 [PubMed - as supplied by publisher] (Source: Revista de Neurologia)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Revista de Neurologia</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3013229</comments>
            <pubDate>Sat, 21 Nov 2009 02:18:35 +0100</pubDate>
            <guid isPermaLink="false">3013229</guid>        </item>
        <item>
            <title>Metabonomics in Ulcerative Colitis: Diagnostics, Biomarker Identification, And Insight into the Pathophysiology</title>
            <link>http://www.medworm.com/index.php?rid=3011630&amp;cid=c_1_60_f&amp;fid=31714&amp;url=http%3A%2F%2Fpubs.acs.org%2Fdoi%2Fabs%2F10.1021%2Fpr9008223%3Fai%3D52c%26af%3DR</link>
            <description>Journal of Proteome Research, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of Proteome Research)</description>
            <author>Journal of Proteome Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3011630</comments>
            <pubDate>Fri, 20 Nov 2009 15:21:50 +0100</pubDate>
            <guid isPermaLink="false">3011630</guid>        </item>
        <item>
            <title>TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice</title>
            <link>http://www.medworm.com/index.php?rid=3010062&amp;cid=c_1_17_f&amp;fid=30386&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1440-1746.2009.06046.x</link>
            <description>Conclusion: Blocking TLR4 by TLR4mAb can prevent the development of DSS-induced colitis through the TLR4-P38MAPK-c-jun pathway. (Source: Journal of Gastroenterology and Hepatology)</description>
            <author>Journal of Gastroenterology and Hepatology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010062</comments>
            <pubDate>Thu, 19 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3010062</guid>        </item>
        <item>
            <title>Asian perspectives in the management of inflammatory bowel disease: Findings from a recent survey</title>
            <link>http://www.medworm.com/index.php?rid=3010067&amp;cid=c_1_17_f&amp;fid=30386&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1440-1746.2009.06024.x</link>
            <description>Conclusion: Clinical practice with regards to IBD diagnosis and management varies within Asia.5-ASA is the preferred treatment and maintenance therapy for mild-to-moderate IBD. (Source: Journal of Gastroenterology and Hepatology)</description>
            <author>Journal of Gastroenterology and Hepatology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3010067</comments>
            <pubDate>Thu, 19 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3010067</guid>        </item>
        <item>
            <title>Differential regulation of interleukin 17 and interferon {gamma} production in inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=3005837&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F12%2F1629%3Frss%3D1</link>
            <description>Conclusions:
Our findings support a role for IL12, TGF&amp;beta; and IL21 in modulating IL17/IFN production in IBD. The abundant IL17 in inflamed IBD mucosa may help explain the relative lack of efficacy of anti-IFN antibodies in clinical trials of Crohn&amp;rsquo;s disease. (Source: Gut)</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005837</comments>
            <pubDate>Wed, 18 Nov 2009 18:02:41 +0100</pubDate>
            <guid isPermaLink="false">3005837</guid>        </item>
        <item>
            <title>Ulcerative colitis: is it in the diet?</title>
            <link>http://www.medworm.com/index.php?rid=3005827&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F12%2F1577%3Frss%3D1</link>
            <description>(Source: Gut)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005827</comments>
            <pubDate>Wed, 18 Nov 2009 18:02:40 +0100</pubDate>
            <guid isPermaLink="false">3005827</guid>        </item>
        <item>
            <title>Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study</title>
            <link>http://www.medworm.com/index.php?rid=3005834&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F12%2F1606%3Frss%3D1</link>
            <description>Conclusions:
The data support a role for dietary linoleic acid in the aetiology of ulcerative colitis. An estimated 30% of cases could be attributed to having dietary intakes higher than the lowest quartile of linoleic acid intake. (Source: Gut)</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005834</comments>
            <pubDate>Wed, 18 Nov 2009 18:02:40 +0100</pubDate>
            <guid isPermaLink="false">3005834</guid>        </item>
        <item>
            <title>Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=3005835&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F12%2F1612%3Frss%3D1</link>
            <description>Conclusion:
Gene array studies of ulcerative colitis mucosal biopsies identified predictive panels of genes for (non-)response to infliximab. Further study of the pathways involved should allow a better understanding of the mechanisms of resistance to infliximab therapy in ulcerative colitis.


ClinicalTrials.gov number, NCT00639821. (Source: Gut)</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005835</comments>
            <pubDate>Wed, 18 Nov 2009 18:02:40 +0100</pubDate>
            <guid isPermaLink="false">3005835</guid>        </item>
        <item>
            <title>Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease</title>
            <link>http://www.medworm.com/index.php?rid=3005836&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F12%2F1620%3Frss%3D1</link>
            <description>Conclusion:
Anti-GP2 autoantibodies constitute novel Crohn&amp;rsquo;s disease-specific markers, the quantification of which could significantly improve the serological diagnosis of IBD. The expression of GP2 in human enterocytes suggests an important role for anti-GP2 response in the pathogenesis of Crohn&amp;rsquo;s disease. (Source: Gut)</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005836</comments>
            <pubDate>Wed, 18 Nov 2009 18:02:40 +0100</pubDate>
            <guid isPermaLink="false">3005836</guid>        </item>
        <item>
            <title>Ulcerative colitis in northern Portugal and Galicia in Spain</title>
            <link>http://www.medworm.com/index.php?rid=3005856&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21170</link>
            <description>Clinical and therapeutic patterns of ulcerative colitis (UC) are variable in different world regions. The purpose of this study was to examine two close independent southern European UC populations from 2 bordering countries and observe how demographic and clinical characteristics of patients can influence the severity of UC.A cross-sectional study was conducted during a 15-month period (September 2005 to December 2006) based on data of 2 Web registries of UC patients. Patients were stratified according to the Montreal Classification and disease severity was defined by the type of treatment taken.A total of 1549 UC patients were included, 1008 (65%) from northern Portugal and 541 (35%) from Galicia (northwest Spain). A female predominance (57%) was observed in Portuguese patients (P &lt; 0.00...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005856</comments>
            <pubDate>Wed, 18 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3005856</guid>        </item>
        <item>
            <title>Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis</title>
            <link>http://www.medworm.com/index.php?rid=3005862&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21132</link>
            <description>Systemic exposure to lipopolysaccharide (LPS) has been linked to clinical disease activity in adults with inflammatory bowel disease (IBD). We hypothesized that markers of LPS exposure and the acute phase response (APR) would be increased in pediatric IBD patients with growth failure, and that LPS signaling would be required for induction of the APR in murine colitis.Serum markers of LPS exposure, endotoxin core IgA antibody (EndoCAb), and the APR, LPS binding protein (LBP) were quantified in pediatric IBD patients and controls. LBP and cytokine production were determined after administration of trinitrobenzene sulfonic acid (TNBS) enemas to mice with genetic deletion of Toll-Like receptor 4 (TLR4), and wildtype (WT) controls.Serum EndoCAb and LBP were significantly elevated in patients wi...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3005862</comments>
            <pubDate>Wed, 18 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3005862</guid>        </item>
        <item>
            <title>Mechanisms of Disease: Inflammatory Bowel Disease</title>
            <link>http://www.medworm.com/index.php?rid=3006978&amp;cid=c_1_49_f&amp;fid=28854&amp;url=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Fshort%2F361%2F21%2F2066%3Frss%3D1%26query%3Dcurrent</link>
            <description>This review gives an account of recent advances in our knowledge of the intestinal immune system and how it becomes perturbed in Crohn's disease and ulcerative colitis. The importance of genetic factors in these diseases has been increasingly recognized, and this article emphasizes their roles. (Source: New England Journal of Medicine)</description>
            <author>New England Journal of Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3006978</comments>
            <pubDate>Wed, 18 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3006978</guid>        </item>
        <item>
            <title>Probiotics and health: a review of the evidence</title>
            <link>http://www.medworm.com/index.php?rid=3001975&amp;cid=c_1_28_f&amp;fid=32623&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1467-3010.2009.01782.x</link>
            <description>Probiotics are live microorganisms [ndash] mainly bacteria [ndash] which when administered in adequate amounts confer a health benefit on the host. There is rising interest in this area, but reports in the media are often conflicting. The aim of this review is to consider the current evidence on the effects of probiotics on health, focusing on gut-related health issues and the immune system, with the objective to provide a clearer picture of whether and how probiotics can be beneficial for health. The outcomes of this review are based on more than 100 original studies, meta-analyses and systematic reviews. A variety of different strains have been used in studies on probiotics, and it is important to remember that the effectiveness of probiotics is strain-specific, which means that each sin...</description>
            <author>Nutrition Bulletin</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3001975</comments>
            <pubDate>Tue, 17 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3001975</guid>        </item>
        <item>
            <title>Validation of the Spanish version of a questionnaire to measure quality of care through the eyes of patients with inflammatory bowel disease (QUOTE-IBD)</title>
            <link>http://www.medworm.com/index.php?rid=2997314&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21156</link>
            <description>The objective was to translate the QUOTE-IBD into Spanish and to determine its validity in patients with IBD.This is a prospective study in 2 phases: first, translation and validation of the Spanish QUOTE-IBD. Translation was based on the validated QUOTE-IBD. Second, once the complete translation was finished, comprehension of the items was assessed with a specific questionnaire in a reduced number of patients. Criterion validity was assessed with the Pearson's correlation coefficient between scores of the QUOTE-IBD and visual analog scales (VAS). In order to analyze the reproducibility of the Spanish QUOTE-IBD, the questionnaire was completed by stable patients twice, with a span of time of at least 4 weeks.A total of 103 patients (CD: 61, UC: 42) were included in the study. Pearson's cor...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2997314</comments>
            <pubDate>Mon, 16 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2997314</guid>        </item>
        <item>
            <title>Gut disorder 'blamed on leaks'</title>
            <link>http://www.medworm.com/index.php?rid=2993972&amp;cid=c_1_26_f&amp;fid=23277&amp;url=http%3A%2F%2Fnews.bbc.co.uk%2Fgo%2Frss%2F-%2F1%2Fhi%2Fhealth%2F8358863.stm</link>
            <description>Genetic research suggests that a leaky gut is a key cause of the inflammatory disorder ulcerative colitis. (Source: BBC News | Health | UK Edition)</description>
            <author>BBC News | Health | UK Edition</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2993972</comments>
            <pubDate>Sun, 15 Nov 2009 17:59:22 +0100</pubDate>
            <guid isPermaLink="false">2993972</guid>        </item>
        <item>
            <title>Synergy of IL-23 and Th17 Cytokines: New Light on Inflammatory Bowel Disease.</title>
            <link>http://www.medworm.com/index.php?rid=3003427&amp;cid=c_1_168_f&amp;fid=37701&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19915978%26dopt%3DAbstract</link>
            <description>Authors: Shen W, Durum SK
    Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, involve an interplay between host genetics and environmental factors including intestinal microbiota. Animal models of IBD have indicated that chronic inflammation can result from over-production of inflammatory responses or deficiencies in key negative regulatory pathways. Recent research advances in both T-helper 1 (Th1) and T-helper 17 (Th17) effect responses have offered new insights on the induction and regulation of mucosal immunity which is linked to the development of IBD. Th17 cytokines, such as IL-17 and IL-22, in combination with IL-23, play crucial roles in intestinal protection and homeostasis. IL-23 is expressed in gut mucosa and tends to orchestrate T-cell-inde...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Neurochemical Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3003427</comments>
            <pubDate>Sat, 14 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3003427</guid>        </item>
        <item>
            <title>Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease.</title>
            <link>http://www.medworm.com/index.php?rid=2987068&amp;cid=c_1_17_f&amp;fid=37909&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19908336%26dopt%3DAbstract</link>
            <description>CONCLUSION: The significantly thinner mucosa of IBD patients showed a predominance of some aerobes specific for particular diseases, their numbers decreased in relation to higher clinical and endoscopic activity of the disease.
    PMID: 19908336 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)</description>
            <author>World Journal of Gastroenterology : WJG</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2987068</comments>
            <pubDate>Fri, 13 Nov 2009 14:46:42 +0100</pubDate>
            <guid isPermaLink="false">2987068</guid>        </item>
        <item>
            <title>Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up</title>
            <link>http://www.medworm.com/index.php?rid=2986656&amp;cid=c_1_17_f&amp;fid=33225&amp;url=http%3A%2F%2Fwww.gastro.theclinics.com%2Farticle%2FPIIS0889855309000740%2Fabstract%3Frss%3Dyes</link>
            <description>This article provides an overview of the current approaches to therapy for CD and UC and focuses on the evidence supporting the rationale for changing paradigms in the management of IBD, including mucosal healing as an end point and earlier use of immunosuppressive and biologic agents, particularly in CD (so-called top-down therapy). (Source: Gastroenterology Clinics of North America)</description>
            <author>Gastroenterology Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986656</comments>
            <pubDate>Fri, 13 Nov 2009 14:14:16 +0100</pubDate>
            <guid isPermaLink="false">2986656</guid>        </item>
        <item>
            <title>Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD</title>
            <link>http://www.medworm.com/index.php?rid=2986658&amp;cid=c_1_17_f&amp;fid=33225&amp;url=http%3A%2F%2Fwww.gastro.theclinics.com%2Farticle%2FPIIS0889855309000764%2Fabstract%3Frss%3Dyes</link>
            <description>This article discusses clinically relevant epidemiology and treatment aspects of pediatric IBD, with special focus on similarities and differences in pediatric and adult IBD. Evidence-based treatment algorithms, with special focus on pediatric studies and care for children, are also highlighted. (Source: Gastroenterology Clinics of North America)</description>
            <author>Gastroenterology Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986658</comments>
            <pubDate>Fri, 13 Nov 2009 14:14:16 +0100</pubDate>
            <guid isPermaLink="false">2986658</guid>        </item>
        <item>
            <title>Pouchitis and Pouch Dysfunction</title>
            <link>http://www.medworm.com/index.php?rid=2986660&amp;cid=c_1_17_f&amp;fid=33225&amp;url=http%3A%2F%2Fwww.gastro.theclinics.com%2Farticle%2FPIIS0889855309000697%2Fabstract%3Frss%3Dyes</link>
            <description>Restorative proctocolectomy with ileal pouch-anal anastomosis has become the surgical treatment of choice for most patients with ulcerative colitis who require surgery. Although the surgical procedure offers a cure in some patients, postoperative inflammatory and noninflammatory complications are common. Pouchitis is the most common long-term complication of the procedure. Pouchitis represents a spectrum of disease processes with heterogeneous risk factors, clinical phenotypes, natural history, and prognosis. Accurate diagnosis and classification are important for proper treatment and prognosis. (Source: Gastroenterology Clinics of North America)</description>
            <author>Gastroenterology Clinics of North America</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986660</comments>
            <pubDate>Fri, 13 Nov 2009 14:14:16 +0100</pubDate>
            <guid isPermaLink="false">2986660</guid>        </item>
        <item>
            <title>Integration of CAM in medical guidelines</title>
            <link>http://www.medworm.com/index.php?rid=2986278&amp;cid=c_1_8_f&amp;fid=38399&amp;url=http%3A%2F%2Fwww.europeanintegrativemedicinejrnl.com%2Farticle%2FPIIS1876382009001188%2Fabstract%3Frss%3Dyes</link>
            <description>Medical guidelines aim to provide all professions involved in the treatment of a disease a systematically developed basis for the diagnosis and therapy. They have growing impact on political, juristic and educational issues in Medicine. In Germany, the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften) is responsible for the coordination of the development of medical guidelines. In June 2009 a total of 154 scientific-medical societies constitute the group of members of the AWMF.The German Society for Natural Medicine (Deutsche Gesellschaft für Naturheilkunde) is currently not a member.Aim: What is necessary to integrate CAM into medical guidelines?To clarify problems and potential of CAM in medical guidelines, the field of gastroenterology was chosen. In Ga...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>European Journal of Integrative Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986278</comments>
            <pubDate>Fri, 13 Nov 2009 13:55:24 +0100</pubDate>
            <guid isPermaLink="false">2986278</guid>        </item>
        <item>
            <title>Phytotherapy in inflammatory bowel diseases (IBD)</title>
            <link>http://www.medworm.com/index.php?rid=2986226&amp;cid=c_1_8_f&amp;fid=38399&amp;url=http%3A%2F%2Fwww.europeanintegrativemedicinejrnl.com%2Farticle%2FPIIS187638200900208X%2Fabstract%3Frss%3Dyes</link>
            <description>Phytotherapy is one of the major fields in “Klassischer Naturheilkunde” in Germany and it is the most frequented one. In 2003 more than 2 billion dollar was spent for over-the-counter herbal treatment.In Germany more than 300,000 patients suffer from IBD, mainly Crohn's disease and ulcerative colitis.In IBD every other patient has personal experience with CAM. Almost 44% of these patients had experience in the field of Herbal therapy, mainly as an adjunct to conventional therapy in an integrated medical treatment approach.One way to implement herbs in the treatment is self-help strategies such as tea. Moreover, there are various herbal preparations with promising results in the treatment of IBD. In Germany there is major interest in the herbs isphagula, frankinsence, myrrh and camomile...</description>
            <author>European Journal of Integrative Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986226</comments>
            <pubDate>Fri, 13 Nov 2009 13:55:06 +0100</pubDate>
            <guid isPermaLink="false">2986226</guid>        </item>
        <item>
            <title>Adsorptive Depletion of α4 Integrinhi- and CX3CR1hi-Expressing Proinflammatory Monocytes in Patients with Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2990619&amp;cid=c_1_17_f&amp;fid=33434&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F549732h70gn47hv1%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;We found high expressions of α4 integrin and CX3CR1 on monocytes in patients with active UC, known to promote the extravasation of CD14+CD16+ monocytes into the mucosa. GMA effectively depletes CD14+CD16+ monocytes and concomitantly increases CD14hiCD16−CCR2low “immature” monocytes; thus GMA was associated with the emergence of less inflammatory monocyte phenotype in circulation.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10620-009-0974-2Authors
		Shin-ichiro Takeda, Chiba University Department of Clinical Cell Biology (F5), Graduate School of Medicine 1-8-1 Inohana, Chuo-ku Chiba-shi 260-8670 JapanToru Sato, Chiba University Department of Clinical Cell Biology (F5), Graduate School of Medicine 1-8-1 Inohana, Chuo-ku Chiba-shi 260...</description>
            <author>Digestive Diseases and Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2990619</comments>
            <pubDate>Thu, 12 Nov 2009 07:25:55 +0100</pubDate>
            <guid isPermaLink="false">2990619</guid>        </item>
        <item>
            <title>[An herpes virus colonic infection in the initial presentation of an ulcerative colitis : diagnostic difficulties.]</title>
            <link>http://www.medworm.com/index.php?rid=3004881&amp;cid=c_1_22_f&amp;fid=36725&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914028%26dopt%3DAbstract</link>
            <description>Authors: Kallel L, Nijaa N, Haouet S, Bahri O, Boubaker J, Filali A
    
    PMID: 19914028 [PubMed - as supplied by publisher] (Source: Presse Medicale)</description>
            <author>Presse Medicale</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3004881</comments>
            <pubDate>Thu, 12 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3004881</guid>        </item>
        <item>
            <title>2010 ASN Abstracts</title>
            <link>http://www.medworm.com/index.php?rid=2979696&amp;cid=c_1_37_f&amp;fid=30483&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1552-6569.2009.00451.x</link>
            <description>Conclusion: VBD can enlarge to significant dimensions, producing compressive symptoms in the brainstem, as well as thrombosis and ischemic strokes. SACE of the dolichoectasia can be effective for the vessel reconstruction, to prevent progression of the dilatation, and other potential clinical events. 3. Three Case Reports of Multiple Carotid and/or Vertebral Artery Dissections in Female Mei Lu, Heather Gornik, Esteban Cheng Ching, Vikram Kashyap, Rishi Gupta Cleveland Clinic Foundation, Cleveland, OH 44195, United States Introduction: Multiple carotid and/or vertebral artery dissections are rare. However, patients with multiple dissections can suffer from severe stroke, leading to significant mobility and mortality. The etiology underlying the bilateral carotid dissection is not clear. The...</description>
            <author>Journal of Neuroimaging</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2979696</comments>
            <pubDate>Wed, 11 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2979696</guid>        </item>
        <item>
            <title>Ulcerative Colitis Maintenance Treatment With 5-ASA: A 1-Year, Randomized Multicentre Study Comparing MMX With Asacol</title>
            <link>http://www.medworm.com/index.php?rid=2982757&amp;cid=c_1_17_f&amp;fid=30406&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F711314%3Fsrc%3Drss</link>
            <description>Investigators evaluated the efficacy and safety of 5-ASA-MMX (2.4 g/d qd) compared with Asacol (2.4 g/d, bid) in the maintenance of left-sided ulcerative colitis.  Alimentary Pharmacology &amp; Therapeutics (Source: Medscape Gastroenterology Headlines)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Medscape Gastroenterology Headlines</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2982757</comments>
            <pubDate>Tue, 10 Nov 2009 17:00:00 +0100</pubDate>
            <guid isPermaLink="false">2982757</guid>        </item>
        <item>
            <title>Il-33 is upregulated in colonocytes of ulcerative colitis.</title>
            <link>http://www.medworm.com/index.php?rid=3004338&amp;cid=c_1_3_f&amp;fid=35627&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19913053%26dopt%3DAbstract</link>
            <description>IL-33 IS UPREGULATED IN COLONOCYTES OF ULCERATIVE COLITIS.
    Immunol Lett. 2009 Nov 10;
    Authors: Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH
    Interleukin-33 (IL-33) is a novel member of the IL-1 cytokine family. It has been shown to elicit a Th2-like cytokine response in immunocompetent cells through binding and activation of the T1/ST2 receptor. IL-33 has recently been associated with immune responses to helminthic intestinal infections, airway inflammation and arthritis in animal models. We now report IL-33 to be produced by colonic epithelial cells in humans and it is highly upregulated in ulcerative colitis (UC). Little mRNA expression was found in control subjects (N=9), whereas patients with UC in remission (N=7) and active UC (N=9) had a 3-fold (p&amp;lt;...</description>
            <author>Immunology Letters</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3004338</comments>
            <pubDate>Tue, 10 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3004338</guid>        </item>
        <item>
            <title>Role of bowel pathophysiology in voiding dysfunction</title>
            <link>http://www.medworm.com/index.php?rid=2979968&amp;cid=c_1_47_f&amp;fid=35929&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm8561r9400118v44%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A great deal of neural overlap and “cross-talk” exists among the pelvic viscera, a prerequisite for normal pelvic physiologic
 function. However, after an acute or chronic irritative or infectious pelvic insult, pelvic “cross-sensitization” may occur,
 leading to the development of chronic pelvic pain and its associated and/or overlapping disorders. As such, comorbid pathophysiologic
 alterations of the bowel and bladder are common, as exemplified by the overlap of irritable bowel syndrome and interstitial
 cystitis/painful bladder syndrome, the two most common chronic pelvic pain disorders. Although less common, voiding dysfunction
 may likewise be seen in inflammatory bowel disease (ulcerative colitis and Crohn’s disease) and diverticulitis. In support
 of t...</description>
            <author>Current Bladder Dysfunction Reports</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2979968</comments>
            <pubDate>Mon, 09 Nov 2009 18:48:40 +0100</pubDate>
            <guid isPermaLink="false">2979968</guid>        </item>
        <item>
            <title>Correlation of Plasma MMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2973500&amp;cid=c_1_60_f&amp;fid=37035&amp;url=http%3A%2F%2Fwww.hindawi.com%2Fjournals%2Fmi%2F2009%2F275072.html</link>
            <description>Conclusion. Plasma MMP-1 and TIMP-1 levels reflect their colonic mucosal expression to some extent in patients with UC. Plasma MMP-1 and TIMP-1, in particular, demonstrate the potential to become biomarkers to clinically diagnose UC, predict its severity, and guide further therapy. (Source: Mediators of Inflammation)</description>
            <author>Mediators of Inflammation</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2973500</comments>
            <pubDate>Mon, 09 Nov 2009 16:16:18 +0100</pubDate>
            <guid isPermaLink="false">2973500</guid>        </item>
        <item>
            <title>TLR9 mRNA expression is upregulated in patients with active ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2975153&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21155</link>
            <description>No abstract. (Source: Inflammatory Bowel Diseases)</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2975153</comments>
            <pubDate>Mon, 09 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2975153</guid>        </item>
        <item>
            <title>Fine-scale geographic variations of inflammatory bowel disease in France: Correlation with socioeconomic and house equipment variables</title>
            <link>http://www.medworm.com/index.php?rid=2975155&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21122</link>
            <description>In a previous study we found a north-south gradient for Crohn's disease (CD) incidence in France. The aim of the present study was to determine if socioeconomic factors may influence the geographic distribution of CD and ulcerative colitis (UC) in France.Using the national health insurance databases, incidence rates of CD and UC were estimated for each of 341 metropolitan &quot;job areas&quot; in 2000-2002. Relationships between incidence rates and relevant contextual variables from the 1999 French census were tested for significance using a Poisson regression. Mapping of smoothed relative risks (sRR) for CD and UC at the scale of job areas, using a Bayesian approach and adjusting for significant contextual variables, was carried out in order to search for geographic variations.CD incidence rates we...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2975155</comments>
            <pubDate>Mon, 09 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2975155</guid>        </item>
        <item>
            <title>Expression of STAT6 and NF-κB p65 in the colon mucosa of patients with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2971558&amp;cid=c_1_22_f&amp;fid=35962&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr478m83775p50v20%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The expression of signal transducer and activator of transcription 6 (STAT6) and nuclear factor-κB (NF-κB) in the colonic
 mucosa of patients with ulcerative colitis (UC) was examined. Real-time polymerase chain reaction and immunohistochemistry
 were used to detect the expression of STAT6 and NF-κB p65 at both mRNA and protein levels in the colonic mucosa of patients
 with UC and healthy volunteers. The results showed that the expression levels of STAT6 and NFκB p65 in the colonic mucosa
 of patients with UC were significantly higher than in normal controls at both mRNA and protein levels. These data suggest
 that STAT6 and NFκB p65 perhaps play an important role in the pathogenesis of UC and underscore the potential value of anti-UC
 strategies in the clinical ma...</description>
            <author>Frontiers of Medicine in China</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971558</comments>
            <pubDate>Fri, 06 Nov 2009 19:10:03 +0100</pubDate>
            <guid isPermaLink="false">2971558</guid>        </item>
        <item>
            <title>Effects of the Gastrin-Releasing Peptide Antagonist RC-3095 in a Rat Model of Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2971520&amp;cid=c_1_17_f&amp;fid=33434&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4644272426572263%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;RC-3095 reduced the colitis severity in a well-established experimental model of IBD. The anti-inflammatory activity of this
 compound was associated with a reduction in the colonic expression of TNF-α. These results suggest that interference with
 GRP pathway might represent a potential new strategy for the treatment of ulcerative colitis that deserves further investigational
 studies.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10620-009-1032-9Authors
		Daniel C. Damin, Federal University of Rio Grande do Sul Division of Coloproctology, Hospital de Clinicas de Porto Alegre, and Department of Surgery, Room 600 Rua Ramiro Barcelos 2350 Porto Alegre RS 90 035-903 BrazilFrederico S. Santos, Federal University of Rio Grande do Sul Division ...</description>
            <author>Digestive Diseases and Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971520</comments>
            <pubDate>Fri, 06 Nov 2009 06:57:21 +0100</pubDate>
            <guid isPermaLink="false">2971520</guid>        </item>
        <item>
            <title>[Comment] Immunosuppression-associated lymphoma in IBD</title>
            <link>http://www.medworm.com/index.php?rid=2965160&amp;cid=c_1_22_f&amp;fid=30418&amp;url=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140673609614872%2Ffulltext%3Frss%3Dyes</link>
            <description>This study is highly relevant: in our experience 30–50% of patients with inflammatory bowel disease are treated with such drugs at some point in the course of their disease The threshold to use thiopurines depends on various factors. The European Crohn's and Colitis Organisation recommends thiopurines for: severe small bowel, ileocaecal, or colonic Crohn's disease if patients have a relapse after or during corticosteroid treatment, in cases of corticosteroid dependency, in the prevention of postoperative recurrence in Crohn's disease, in moderate to severe ulcerative colitis that requires multiple courses of corticosteroids, or in cases of corticodependent or refractory ulcerative colitis. A Cochrane review of the efficacy of thiopurines for inducing remission in active Crohn's disease s...</description>
            <author>LANCET</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2965160</comments>
            <pubDate>Fri, 06 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2965160</guid>        </item>
        <item>
            <title>Researchers Discover Mutations in Two Genes that Cause Early-Onset Inflammatory Bowel Disease</title>
            <link>http://www.medworm.com/index.php?rid=2963824&amp;cid=c_1_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fenter%2Fmedlineplus%2Frss%3Ffeed%3DTodays%2520MedlinePlus%2520Health%2520News%26url%3Dhttp%253A%252F%252Fwww%252Enih%252Egov%252Fnews%252Fhealth%252Fnov2009%252Fnlm%252D05%252Ehtm</link>
            <description>Source: National Center for Biotechnology Information, National Library of Medicine 
   	
    Related MedlinePlus Topic: Ulcerative Colitis (Source: MedlinePlus Health News)</description>
            <author>MedlinePlus Health News</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2963824</comments>
            <pubDate>Thu, 05 Nov 2009 18:39:41 +0100</pubDate>
            <guid isPermaLink="false">2963824</guid>        </item>
        <item>
            <title>Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease.</title>
            <link>http://www.medworm.com/index.php?rid=2960133&amp;cid=c_1_67_f&amp;fid=36720&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19885626%26dopt%3DAbstract</link>
            <description>Authors: Ohira M, Oshitani N, Hosomi S, Watanabe K, Yamagami H, Tominaga K, Watanabe T, Fujiwara Y, Maeda K, Hirakawa K, Arakawa T
    Crohn's disease is associated with increased permeability of the intestine even in quiescent patients. Increased intestinal permeability may cause dysregulated immunological responses in the intestinal mucosa that leads to chronic intestinal inflammation. Tight junction proteins contribute to intestinal permeability, and functional abnormality and dislocation of such proteins may cause increased intestinal permeability. We studied the expression of tight junction proteins Rab13, vasodilator-stimulated phosphoprotein (VASP), zonula occludin-1 (ZO-1), and F-actin in the intestinal epithelium of patients with inactive inflammatory bowel disease. Surgical sampl...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>International Journal of Molecular Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960133</comments>
            <pubDate>Thu, 05 Nov 2009 12:42:20 +0100</pubDate>
            <guid isPermaLink="false">2960133</guid>        </item>
        <item>
            <title>Effect of compound Sophorae Flavescentis Jiechangrong capsule on expression of NF-κB p65 and STAT6 in the intestinal mucosa of patients with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2968963&amp;cid=c_1_22_f&amp;fid=35962&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn226q4261r476752%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The effects of compound Sophorae Flavescentis Jiechangrong capsule (CSFJC) on the expression of nuclear factor-κB p65 (NF-κB
 p65) and signal transducer and activator of transcription 6 (STAT6) in the intestinal mucosa of patients with ulcerative colitis
 and the possible mechanism were investigated. Eighteen patients with ulcerative colitis were randomly divided into a traditional
 Chinese medicine (TCM) group (n = 11) treated by CSFJC and a western medicine (WM) group (n = 7) treated by Sulfasalazine tablets. The treatment duration lasted eight weeks. Before and after the treatment, the symptoms
 and the physical signs were observed, and the routine stool test, the colonoscopy, and pathological examination were performed
 in the two groups. The expression levels of ...</description>
            <author>Frontiers of Medicine in China</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2968963</comments>
            <pubDate>Thu, 05 Nov 2009 07:45:21 +0100</pubDate>
            <guid isPermaLink="false">2968963</guid>        </item>
        <item>
            <title>Gene Discovery Gives Clues to Crohn's Disease, Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2962586&amp;cid=c_1_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fenter%2Fmedlineplus%2Frss%3Ffeed%3DTodays%2520MedlinePlus%2520Health%2520News%26url%3Dhttp%253A%252F%252Fwww%252Enlm%252Enih%252Egov%252Fmedlineplus%252Fnews%252Ffullstory%255F91461%252Ehtml</link>
            <description>Mutation is tied to a protein implicated in rare form of bowel disorder, researchers say Source: HealthDay 
   	
    Related MedlinePlus Topics: Crohn's Disease, Genes and Gene Therapy, Ulcerative Colitis (Source: MedlinePlus Health News)</description>
            <author>MedlinePlus Health News</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2962586</comments>
            <pubDate>Wed, 04 Nov 2009 22:00:00 +0100</pubDate>
            <guid isPermaLink="false">2962586</guid>        </item>
        <item>
            <title>Diagnostic and Treatment Algorithms of Ulcerative Colitis in Ukraine</title>
            <link>http://www.medworm.com/index.php?rid=2964888&amp;cid=c_1_17_f&amp;fid=33521&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D233296</link>
            <description>Dig Dis 2009;27:550-554 (DOI:10.1159/000233296) (Source: Digestive Diseases)</description>
            <author>Digestive Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2964888</comments>
            <pubDate>Tue, 03 Nov 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2964888</guid>        </item>
        <item>
            <title>Medical Management of Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2964889&amp;cid=c_1_17_f&amp;fid=33521&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D233295</link>
            <description>Dig Dis 2009;27:542-549 (DOI:10.1159/000233295) (Source: Digestive Diseases)</description>
            <author>Digestive Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2964889</comments>
            <pubDate>Tue, 03 Nov 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2964889</guid>        </item>
        <item>
            <title>Once-Daily Mesalamine as Effective as Twice-Daily Treatment for Maintenance of Remission in UC</title>
            <link>http://www.medworm.com/index.php?rid=2953611&amp;cid=c_1_49_f&amp;fid=36063&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F711692%3Fsrc%3Drss</link>
            <description>Patients with ulcerative colitis are more compliant with once-daily delayed-release mesalamine without a loss of efficacy in maintaining remission over the standard twice-daily regimen.  Medscape Medical News (Source: Medscape Internal Medicine Headlines)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Medscape Internal Medicine Headlines</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2953611</comments>
            <pubDate>Tue, 03 Nov 2009 15:14:38 +0100</pubDate>
            <guid isPermaLink="false">2953611</guid>        </item>
        <item>
            <title>Superfood Profile: Discover the Many Health Benefits of Chlorella</title>
            <link>http://www.medworm.com/index.php?rid=2954230&amp;cid=c_1_91_f&amp;fid=36976&amp;url=http%3A%2F%2Fwww.NaturalNews.com%2F027384_chlorella_health_superfood.html</link>
            <description>(NaturalNews) With the quality of commercially-grown produce declining rapidly, obtaining nutritious fruits and vegetables is not an easy task. Few of us eat enough fruits and vegetables on a daily basis; it's a fact that grows more true with each generation. So how do we answer these issues, knowing the bounty of nutrients we're missing? One solution is chlorella, a green single-cell algae that packs a huge nutritious punch.Chlorella is an astounding package of complete nutrition, considering it is such a simple life form, which is probably why it is often referred to as nature's multivitamin. The synergistic nature of chlorella's nutrients is undeniable. All of its natural properties function together in a way individual supplements can't touch. Chlorella is famous for providing a vast a...</description>
            <author>NaturalNews.com</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2954230</comments>
            <pubDate>Tue, 03 Nov 2009 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">2954230</guid>        </item>
        <item>
            <title>Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2952242&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21161</link>
            <description>Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated the safety and preliminary efficacy of exogenous AP administered to patients with UC in an open-label, first-in-patient exploratory trial, conducted in the Internal Medicine and Gastroenterology hospital departments in the Czech Republic and Italy.Twenty-one patients were enrolled (13 females), age 23-54 years, with steroid- and/or immunosuppressant-refractory, moderate/severe UC (Mayo score 6-11). Oral AP enzyme 30,000 U was administered daily for 7 days, intraduodenally. Efficacy outcomes were changes in Mayo score at Day 21 posttreatment; changes in Modified Truelove-Witts Severity index (MTWSI) at Days 21, 63; C-...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2952242</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2952242</guid>        </item>
        <item>
            <title>Pouchitis disease activity index (PDAI) does not predict patients with symptoms of pouchitis who will respond to antibiotics</title>
            <link>http://www.medworm.com/index.php?rid=2957590&amp;cid=c_1_43_f&amp;fid=33293&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3345016q0650h377%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Antibiotic treatment was effective in a considerable number of ulcerative colitis patients whose PDAI score was less than
 7 after IPAA.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00595-009-3988-7Authors
		Mohei Kohyama, Hiroshima General Hospital Department of Surgery 1-3-3 Jigozen, Hatsukaichi Hiroshima 738-8503 JapanYoshio Takesue, Hyogo College of Medicine Department of Infection Control and Prevention Nishinomiya, Hyogo JapanHiroki Ohge, Hiroshima University Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences Hiroshima JapanYoshiaki Murakami, Hiroshima University Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences Hiroshima JapanFumio Shim...</description>
            <author>Surgery Today</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2957590</comments>
            <pubDate>Mon, 02 Nov 2009 17:57:18 +0100</pubDate>
            <guid isPermaLink="false">2957590</guid>        </item>
        <item>
            <title>Adalimumab Initially Effective in Infliximab-Resistant Ulcerative Colitis, But Effects Are Not Durable</title>
            <link>http://www.medworm.com/index.php?rid=2949983&amp;cid=c_1_49_f&amp;fid=36063&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F711606%3Fsrc%3Drss</link>
            <description>Medscape Medical News (Source: Medscape Internal Medicine Headlines)</description>
            <author>Medscape Internal Medicine Headlines</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2949983</comments>
            <pubDate>Mon, 02 Nov 2009 13:45:19 +0100</pubDate>
            <guid isPermaLink="false">2949983</guid>        </item>
        <item>
            <title>Colonoscopy Key for People with IBD</title>
            <link>http://www.medworm.com/index.php?rid=2951720&amp;cid=c_1_6_f&amp;fid=38305&amp;url=http%3A%2F%2Fcoloncancer.about.com%2Fb%2F2009%2F11%2F02%2Fcolonoscopy-key-for-people-with-ibd.htm</link>
            <description>Inflammatory bowel disease (IBD) refers to a group of conditions that cause pain and damage in the gastrointestinal tract. Crohn's disease and ulcerative colitis are the two most common inflammatory bowel diseases. Symptoms of these conditions include abdominal pain, weight loss, fever, rectal bleeding, blood in the stools, diarrhea, and skin and eye irritation.
One of the most important things to know about IBD is that having it can significantly increase your risk of developing colon cancer. It's a scary thought, and it seems completely unfair that in addition to the pain and suffering that can come with IBD itself, comes a higher risk of a potentially life-threatening cancer.
Fortunately, there something you can do to greatly increase the odds that if you do develop colon cancer, you wi...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>About.com Colon Cancer</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2951720</comments>
            <pubDate>Mon, 02 Nov 2009 13:25:40 +0100</pubDate>
            <guid isPermaLink="false">2951720</guid>        </item>
        <item>
            <title>Factors associated with radiation exposure in patients with inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=2949195&amp;cid=c_1_13_f&amp;fid=32539&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2009.04140.x</link>
            <description>Conclusions Diagnosis of CD, IBD-related surgery, prednisone use, first year of diagnosis and age on the upper quartile are independent predictors of increased exposure in IBD patients. Alternative investigations which do not require radiation exposure should be considered for patients at risk for increased radiation exposure. (Source: Alimentary Pharmacology and Therapeutics)</description>
            <author>Alimentary Pharmacology and Therapeutics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2949195</comments>
            <pubDate>Mon, 02 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2949195</guid>        </item>
        <item>
            <title>Conference report: Possible link between thiopurines and skin cancer in IBD?</title>
            <link>http://www.medworm.com/index.php?rid=2951676&amp;cid=c_1_6_f&amp;fid=31120&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---November%2F02%2FConference-report-Possible-link-between-thiopurines-and-skin-cancer-in-IBD%2F</link>
            <description>Source: ScienceDaily
Area: News
 According to the findings of a retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting, patients with inflammatory bowel disease (IBD) may be at risk of developing non-melanoma skin cancer (NMSC), especially if they are receiving treatment with a thiopurine.&amp;nbsp; 
 &amp;nbsp; 
 Researchers examined the records of 26,403 patients with Crohn's disease (CD) and 26,974 patients with ulcerative colitis (UC), to investigate whether IBD could be associated with a higher risk of NMSC, and whether this risk increased in association with immunosuppressants and biological medications.&amp;nbsp; Each patient was matched (according to age, gender, and region) with three randomly selected controls who did not have IBD.&amp;n...</description>
            <author>NeLM - Oncology</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2951676</comments>
            <pubDate>Mon, 02 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2951676</guid>        </item>
        <item>
            <title>Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding</title>
            <link>http://www.medworm.com/index.php?rid=2952245&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21154</link>
            <description>The aim of this article is to critically review available data regarding the safety of immunomodulators and biological therapies during pregnancy and breast-feeding in women with inflammatory bowel disease. Methotrexate and thalidomide can cause congenital anomalies and are contraindicated during pregnancy (and breast-feeding). Although thiopurines have a Food and Drug Administration (FDA) rating D, available data suggest that these drugs are safe and well tolerated during pregnancy. Although traditionally women receiving azathioprine or mercaptopurine have been discouraged from breast-feeding because of theoretical potential risks, it seems that these drugs may be safe in this scenario. Treatment with cyclosporine for steroid-refractory ulcerative colitis (UC) during pregnancy can be cons...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2952245</comments>
            <pubDate>Mon, 02 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2952245</guid>        </item>
        <item>
            <title>Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France</title>
            <link>http://www.medworm.com/index.php?rid=2952247&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21147</link>
            <description>Data regarding the prevalence of hepatitis C (HCV) and hepatitis B (HBV) in inflammatory bowel disease (IBD) patients are conflicting.In all, 315 IBD (252 Crohn's disease [CD] and 63 ulcerative colitis [UC]) patients were consecutively recruited between June 2005 and May 2009.The median age was 33 years (interquartile range [IQR]: 24-43) and median disease duration was 5 years (IQR: 2-11). Present and/or past HBV and HCV infection was found in 2.86% of 315 patients (CD: HBsAg 0.79%, anti-HBc 2.78%, anti-HCV 0.79%; UC: HBsAg 1.59%, anti-HBc 1.59%, anti-HCV 1.59%). Effective vaccination (anti-HBs without anti-HBc) was present in 48.9% of 315 patients. In multivariate analysis, age at diagnosis over 31 years (odds ratio [OR] 0.29; 95% confidence interval [CI] 0.15-0.58; P = 0.005), disease du...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2952247</comments>
            <pubDate>Mon, 02 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2952247</guid>        </item>
        <item>
            <title>Crohn's Disease</title>
            <link>http://www.medworm.com/index.php?rid=2949135&amp;cid=c_1_10_f&amp;fid=37293&amp;url=http%3A%2F%2Fwww.springer.com%2Fmedicine%2Fsurgery%2Fbook%2F978-88-470-1471-8</link>
            <description>A Multidisciplinary Approach series: Updates in Surgery Crohn's disease is an inflammatory bowel disease, whose symptoms are similar to other intestinal disorders, such as irritable bowel syndrome and ulcerative colitis; it can therefore be difficult to diagnose. Its knowledge and understanding have increased considerably in the last years; new advances in genetics, medical and surgical management offer today new possibilities for ... (Source: Springer Medicine titles)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Springer Medicine  titles</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2949135</comments>
            <pubDate>Sat, 31 Oct 2009 00:03:31 +0100</pubDate>
            <guid isPermaLink="false">2949135</guid>        </item>
        <item>
            <title>Pyoderma gangrenosum complicating an implantable cardioverter defibrillator wound in a patient with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2940834&amp;cid=c_1_7_f&amp;fid=29162&amp;url=http%3A%2F%2Feuropace.oxfordjournals.org%2Fcgi%2Fcontent%2Fshort%2F11%2F11%2F1482%3Frss%3D1</link>
            <description>(Source: Europace)</description>
            <author>Europace</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2940834</comments>
            <pubDate>Fri, 30 Oct 2009 08:49:33 +0100</pubDate>
            <guid isPermaLink="false">2940834</guid>        </item>
        <item>
            <title>Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43</title>
            <link>http://www.medworm.com/index.php?rid=2937375&amp;cid=c_1_39_f&amp;fid=32084&amp;url=http%3A%2F%2Ffeeds.nature.com%2F%7Er%2Fnature%2Frss%2Fcurrent%2F%7E3%2FUokFUg6tnM8%2Fnature08530</link>
            <description>Authors: Kendle M. Maslowski, Angelica T. Vieira, Aylwin Ng, Jan Kranich, Frederic Sierro, Di Yu, Heidi C. Schilter, Michael S. Rolph, Fabienne Mackay, David Artis, Ramnik J. Xavier, Mauro M. Teixeira &amp; Charles R. Mackay
The immune system responds to pathogens by a variety of pattern recognition molecules such as the Toll-like receptors (TLRs), which promote recognition of dangerous foreign pathogens. However, recent evidence indicates that normal intestinal microbiota might also positively influence immune responses, and protect against the development of inflammatory diseases. One of these elements may be short-chain fatty acids (SCFAs), which are produced by fermentation of dietary fibre by intestinal microbiota. A feature of human ulcerative colitis and other colitic diseases is a ...</description>
            <author>Nature</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2937375</comments>
            <pubDate>Thu, 29 Oct 2009 15:14:33 +0100</pubDate>
            <guid isPermaLink="false">2937375</guid>        </item>
        <item>
            <title>Inflammatory bowel disease (ulcerative colitis) presenting as a risk factor for recurrent thromboembolic events: a case report</title>
            <link>http://www.medworm.com/index.php?rid=2936594&amp;cid=c_1_22_f&amp;fid=30439&amp;url=http%3A%2F%2Fwww.casesjournal.com%2Fcontent%2F2%2F1%2F173</link>
            <description>Ulcerative colitis (UC), a member of the family of inflammatory bowel disease (IBD), occurs worldwide. It has an incidence which in recent years has been rising in areas such as Southern Europe and Asia, while remaining relatively constant in Northern Europe and North America.Complications associated with UC include toxic dilatation, perforation, carcinoma and massive haemorrhage. Extra-intestinal complications also occur and these include Thromboemboli (TE).Thromboembolic disease has a greater incidence and recurrence rate among patients with IBD than the general population. (Source: BioMed Central)</description>
            <author>BioMed Central</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2936594</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2936594</guid>        </item>
        <item>
            <title>A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease?</title>
            <link>http://www.medworm.com/index.php?rid=2947120&amp;cid=c_1_17_f&amp;fid=30378&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19875702%26dopt%3DAbstract</link>
            <description>Authors: Kalischuk LD, Buret AG
    The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are T cell-mediated diseases that are characterized by chronic, relapsing inflammation of the intestinal tract. The pathogenesis of IBD involves the complex interaction between the intestinal microflora, host genetic and immune factors, and environmental stimuli. Epidemiological analyses have implicated acute bacterial enteritis as one of the factors that may incite or exacerbate IBD in susceptible individuals. In this review, we examine how interactions between the common enteric pathogen Campylobacter jejuni, the host intestinal epithelium, and resident intestinal microflora may contribute to the pathogenesis of IBD. Recent experimental evidence indicates that C. jejuni may ...</description>
            <author>Am J Physiol Gastroi...</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947120</comments>
            <pubDate>Thu, 29 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2947120</guid>        </item>
        <item>
            <title>Study demonstrates effectiveness of once-daily dose of Asacol for ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2937079&amp;cid=c_1_34_f&amp;fid=36544&amp;url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYos6J4M7NUI%2Fstudy-demonstrates-effectiveness-once-daily-asacol-ulcerative-colitis-8330.html</link>
            <description>Largest prospective controlled trial in UC meets primary
endpoint of non-inferiority for maintaining remission in UC
patients
TORONTO, October 28, 2009 – Results from the largest
prospective controlled ulcerative colitis (UC) trial conducted... (Source: Drugs.com - Clinical Trials)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Drugs.com - Clinical Trials</author>
            <type>clinical trials</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2937079</comments>
            <pubDate>Wed, 28 Oct 2009 20:40:52 +0100</pubDate>
            <guid isPermaLink="false">2937079</guid>        </item>
        <item>
            <title>Bowel Disease Treatment May Raise Skin Cancer Risk</title>
            <link>http://www.medworm.com/index.php?rid=2929416&amp;cid=c_1_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fenter%2Fmedlineplus%2Frss%3Ffeed%3DTodays%2520MedlinePlus%2520Health%2520News%26url%3Dhttp%253A%252F%252Fwww%252Enlm%252Enih%252Egov%252Fmedlineplus%252Fnews%252Ffullstory%255F91059%252Ehtml</link>
            <description>Rates of non-melanoma cancer higher in patients with Crohn's, ulcerative colitis, study finds Source: HealthDay 
   	
    Related MedlinePlus Topics: Crohn's Disease, Skin Cancer, Ulcerative Colitis (Source: MedlinePlus Health News)</description>
            <author>MedlinePlus Health News</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2929416</comments>
            <pubDate>Mon, 26 Oct 2009 16:00:00 +0100</pubDate>
            <guid isPermaLink="false">2929416</guid>        </item>
        <item>
            <title>Surgery for low-grade colorectal dysplasia in ulcerative colitis: Decisions, decisions</title>
            <link>http://www.medworm.com/index.php?rid=2921766&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21138</link>
            <description>No abstract. (Source: Inflammatory Bowel Diseases)</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2921766</comments>
            <pubDate>Thu, 22 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2921766</guid>        </item>
        <item>
            <title>Soluble adhesion molecules in inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=2924283&amp;cid=c_1_22_f&amp;fid=35978&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu44r0q24l1831639%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;sICAM-1 and sE-selecin are elevated in the serum of paients with IBD but CRP and microalbuminuria reflect clinical disease
 activity more accurately. This study does not support the routine use of soluble adhesion molecules as disease activity markers
 in IBD.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/BF03168821Authors
		M. G. Goggins, Trinity College and St James’s Hospital Departments of Clinical Medicine and Gastroenterology Dublin IrelandJ. Goh, Trinity College and St James’s Hospital Departments of Clinical Medicine and Gastroenterology Dublin IrelandM. A. O’Connell, Trinity College and St James’s Hospital Departments of Clinical Medicine and Gastroenterology Dublin IrelandD. G. Weir, Trinity College and St James’s Hospital D...</description>
            <author>Irish Journal of Medical Science</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2924283</comments>
            <pubDate>Thu, 22 Oct 2009 18:43:40 +0100</pubDate>
            <guid isPermaLink="false">2924283</guid>        </item>
        <item>
            <title>Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract</title>
            <link>http://www.medworm.com/index.php?rid=2913970&amp;cid=c_1_17_f&amp;fid=33702&amp;url=http%3A%2F%2Fajpgi.physiology.org%2Fcgi%2Fcontent%2Fabstract%2F297%2F5%2FG861%3Frss%3D1</link>
            <description>It is unclear why patients with inflammation of the distal bowel complain of symptoms referable to the upper gastrointestinal tract, specifically to gastric emptying (GE) disturbances. Thus we aimed to determine occurrence and putative pathomechanisms of gastric motor disorders in such patients. Thirteen healthy subjects (CON), 13 patients with Crohn's disease (CD), 10 with ulcerative colitis (UC), and 7 with diverticulitis (DIV) underwent a standardized 13C-octanoic acid gastric emptying breath test. Plasma glucose, CCK, peptide YY, and glucagon-like peptide-1 (GLP-1) were measured periodically and correlated with GE parameters. Results were given in means &amp;plusmn; SD. Compared with CON, GE half time (T) was prolonged by 50% in CD (115 &amp;plusmn; 55 vs. 182 &amp;plusmn; 95 min, P = 0.037). Six ...</description>
            <author>AJP: Gastrointestinal and Liver Physiology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2913970</comments>
            <pubDate>Wed, 21 Oct 2009 21:20:56 +0100</pubDate>
            <guid isPermaLink="false">2913970</guid>        </item>
        <item>
            <title>Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2919018&amp;cid=c_1_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr4v12p1ju8703180%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Infliximab induction regimen appears to be a cost-effective treatment option for UC patients hospitalised with an acute exacerbation.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0199-5Authors
		Yogesh Suresh Punekar, Schering-Plough Ltd Welwyn Garden City AL7 1TW UKNeil Hawkins, Oxford Outcomes Oxford UK
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2919018</comments>
            <pubDate>Wed, 21 Oct 2009 09:06:10 +0100</pubDate>
            <guid isPermaLink="false">2919018</guid>        </item>
        <item>
            <title>The value of histological changes and immunohistochemical markers Ki67 and p53 in the assessment of ulcerative colitis related dysplasia</title>
            <link>http://www.medworm.com/index.php?rid=2918088&amp;cid=c_1_22_f&amp;fid=33446&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp074r374894x1583%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The risk of carcinoma increases in patients with a 10-year or longer duration of ulcerative colitis (UC). To search for a
 more objective parameter to assess epithelial dysplasia. The study comprised 25 cases of longstanding UC: 7 cases with regenerative
 atypia, 7 with low grade dysplasia, 7 with high grade dysplasia, and 4 cases indefinite for dysplasia. The colonic biopsies
 obtained during endoscopy were stained with H&amp;E to identify the aforementioned categories. Seventy-five sections from biopsy
 specimens were stained immunohistochemically to detect differences in the frequency and pattern of nuclei positive for the
 proliferation marker Ki67 and p53. In high grade dysplasia, the distribution of Ki67 positive cells was diffuse throughout
 the full length of the cr...</description>
            <author>Central European Journal of Medicine</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2918088</comments>
            <pubDate>Wed, 21 Oct 2009 08:59:44 +0100</pubDate>
            <guid isPermaLink="false">2918088</guid>        </item>
        <item>
            <title>Surveillance for Dysplasia in Patients with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: An Interim Analysis</title>
            <link>http://www.medworm.com/index.php?rid=2913969&amp;cid=c_1_17_f&amp;fid=33434&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F427uw2746p570436%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;A study with longer follow-up after IPAA should precede any attempt to recommend routine surveillance. However, the finding
 of dysplasia early after surgery underscores the importance of early pouch surveillance in our population, at least until
 definite predisposing variables are identified.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10620-009-1006-yAuthors
		Jorge D. Meléndez Hernández, University of Puerto Rico School of Medicine Department of Internal Medicine San Juan Puerto RicoCarlos Jiménez-Huyke, University of Puerto Rico School of Medicine Department of Internal Medicine San Juan Puerto RicoKathia Rosado, University of Puerto Rico School of Medicine Department of Pathology and Laboratory Medicine San Juan Puerto RicoCarmen ...</description>
            <author>Digestive Diseases and Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2913969</comments>
            <pubDate>Tue, 20 Oct 2009 16:26:28 +0100</pubDate>
            <guid isPermaLink="false">2913969</guid>        </item>
        <item>
            <title>Treatment For Inflammatory Bowel Disease Increases The Risk Of Infection-Related Cancers</title>
            <link>http://www.medworm.com/index.php?rid=2905567&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F167871.php</link>
            <description>Patients with Crohn's disease or ulcerative colitis (collectively referred to as inflammatory bowel disease [IBD]) regularly receive treatment with thiopurine drugs to maintain remission. But an Article published Online First (http://www.thelancet. (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905567</comments>
            <pubDate>Tue, 20 Oct 2009 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">2905567</guid>        </item>
        <item>
            <title>Colocolic intussusception in a patient with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2910210&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21123</link>
            <description>No abstract. (Source: Inflammatory Bowel Diseases)</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2910210</comments>
            <pubDate>Mon, 19 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2910210</guid>        </item>
        <item>
            <title>Med Sci Monit 2009; 15(11):CR563-572 &amp;quot;Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis&amp;quot;</title>
            <link>http://www.medworm.com/index.php?rid=2904055&amp;cid=c_1_39_f&amp;fid=36926&amp;url=http%3A%2F%2Fwww.medscimonit.com%2Fabstracted.php%3Ficid%3D878240%26level%3D5</link>
            <description>Conclusions:	A chronic low-grade activation of coagulation exists in ulcerative colitis, regardless of disease activity, and it might be implicated in disease pathogenesis. (Source: Medical Science Monitor)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Medical Science Monitor</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2904055</comments>
            <pubDate>Mon, 19 Oct 2009 11:44:00 +0100</pubDate>
            <guid isPermaLink="false">2904055</guid>        </item>
        <item>
            <title>Inflammatory Bowel Disease (IBD): Treatment Increases The Risk Of Infection-Related Cancers</title>
            <link>http://www.medworm.com/index.php?rid=2903340&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F167725.php</link>
            <description>Ulcerative colitis or Crohn's disease is generally referred to as inflammatory bowel disease (IBD). Patients regularly receive treatment with thiopurine drugs to sustain remission. An article published Online First and in a future edition of The Lancet shows that this treatment increases the risk of malignant lymphoproliferative disorders (LD). (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2903340</comments>
            <pubDate>Mon, 19 Oct 2009 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">2903340</guid>        </item>
        <item>
            <title>MR metabolomics of fecal extracts: applications in the study of bowel diseases.</title>
            <link>http://www.medworm.com/index.php?rid=2909524&amp;cid=c_1_59_f&amp;fid=36809&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19842159%26dopt%3DAbstract</link>
            <description>Authors: Bezabeh T, Somorjai RL, Smith IC
    NMR-based metabolomics is becoming a useful tool in the study of body fluids and has a strong potential to contribute to disease diagnosis. While applications on urine and serum have been the focus to date, there are a number of other body fluids that are readily available and could potentially be used for metabolomics-based disease diagnosis. One such body fluid is stool or fecal extract. Given its contact with and transient stay in the colon and rectum, stool carries a lot of useful information regarding the health/disease status of both the colon and the rectum. This could be particularly useful for the non-invasive diagnosis of colorectal cancer and inflammatory bowel disease-the two bowel diseases that are very common and pose significant ...</description>
            <author>Magnetic Resonance in Chemistry : MRC</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2909524</comments>
            <pubDate>Sun, 18 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2909524</guid>        </item>
        <item>
            <title>IBD Treatment Could Boost Risk of Lymphomas (CME/CE)</title>
            <link>http://www.medworm.com/index.php?rid=2903728&amp;cid=c_1_17_f&amp;fid=30405&amp;url=http%3A%2F%2Fwww.medpagetoday.com%2FGastroenterology%2FInflammatoryBowelDisease%2F16471</link>
            <description>Thiopurine drugs used to keep patients with Crohn's disease or ulcerative colitis in remission may increase the risk of malignant lymphoproliferative disorders, researchers say. (Source: MedPage Today Gastroenterology)</description>
            <author>MedPage Today Gastroenterology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2903728</comments>
            <pubDate>Sun, 18 Oct 2009 22:30:00 +0100</pubDate>
            <guid isPermaLink="false">2903728</guid>        </item>
        <item>
            <title>Bowel Disease Drugs Increase Cancer Risk</title>
            <link>http://www.medworm.com/index.php?rid=2905160&amp;cid=c_1_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fenter%2Fmedlineplus%2Frss%3Ffeed%3DTodays%2520MedlinePlus%2520Health%2520News%26url%3Dhttp%253A%252F%252Fwww%252Enlm%252Enih%252Egov%252Fmedlineplus%252Fnews%252Ffullstory%255F90755%252Ehtml</link>
            <description>Some treatments for inflammatory bowel disease increase the risk of infection-related cancers, French scientists said on Monday, but the benefits of the drugs still outweigh the risks. Source: Reuters Health 
   	
    Related MedlinePlus Topics: Crohn's Disease, Lymphoma, Ulcerative Colitis (Source: MedlinePlus Health News)</description>
            <author>MedlinePlus Health News</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905160</comments>
            <pubDate>Sun, 18 Oct 2009 22:28:04 +0100</pubDate>
            <guid isPermaLink="false">2905160</guid>        </item>
        <item>
            <title>Inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=2900414&amp;cid=c_1_16_f&amp;fid=36644&amp;url=http%3A%2F%2Fwww.ooooe.net%2Farticle%2FPIIS1079210409004867%2Fabstract%3Frss%3Dyes</link>
            <description>This article reviews clinical presentation, diagnostic criteria, and therapeutic modalities for the 2 main types of inflammatory bowel disease and discusses manifestations of these conditions in the oral cavity. The role of the oral health care provider in timely recognition and referral for medical work-up as well as management of oral complaints is also emphasized. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2900414</comments>
            <pubDate>Sat, 17 Oct 2009 13:07:42 +0100</pubDate>
            <guid isPermaLink="false">2900414</guid>        </item>
        <item>
            <title>Biomedical Research Centre Searches For Immunological Biomarkers</title>
            <link>http://www.medworm.com/index.php?rid=2899955&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F167697.php</link>
            <description>Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection. (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2899955</comments>
            <pubDate>Sat, 17 Oct 2009 08:00:00 +0100</pubDate>
            <guid isPermaLink="false">2899955</guid>        </item>
        <item>
            <title>Two indices accurately, noninvasively assess UC disease activity</title>
            <link>http://www.medworm.com/index.php?rid=2896439&amp;cid=c_1_17_f&amp;fid=36313&amp;url=http%3A%2F%2Fwww.medwire-news.md%2F41%2F84819%2FGastroenterology%2FTwo_indices_accurately%2C_noninvasively_assess_UC_disease_activity.html</link>
            <description>Researchers have identified two clinical indices that they say are “valid, reliable and responsive” ways to noninvasively assess disease activity in ulcerative colitis patients. (Source: MedWire News - Gastroenterology)</description>
            <author>MedWire News - Gastroenterology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896439</comments>
            <pubDate>Fri, 16 Oct 2009 13:13:33 +0100</pubDate>
            <guid isPermaLink="false">2896439</guid>        </item>
        <item>
            <title>Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease</title>
            <link>http://www.medworm.com/index.php?rid=2906410&amp;cid=c_1_17_f&amp;fid=33434&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F464m74545622h658%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Total parenteral iron replacement with LMW iron dextran is an easy, safe, and effective alternative method for treating iron
 deficiency anemia in IBD. Harmless adverse reactions may develop in a minority of patients.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10620-009-1022-yAuthors
		Ioannis E. Koutroubakis, University Hospital Heraklion Department of Gastroenterology P.O. Box 1352 71110 Heraklion, Crete GreecePantelis Oustamanolakis, University Hospital Heraklion Department of Gastroenterology P.O. Box 1352 71110 Heraklion, Crete GreeceChristos Karakoidas, Evangelismos Hospital Athens 1st Department of Gastroenterology Athens GreeceGerassimos J. Mantzaris, Evangelismos Hospital Athens 1st Department of Gastroenterology Athens GreeceEli...</description>
            <author>Digestive Diseases and Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906410</comments>
            <pubDate>Fri, 16 Oct 2009 09:35:19 +0100</pubDate>
            <guid isPermaLink="false">2906410</guid>        </item>
        <item>
            <title>TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease</title>
            <link>http://www.medworm.com/index.php?rid=2896440&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21124</link>
            <description>Tumor necrosis factor (TNF)-like protein 1A (TL1A) is a member of the TNF superfamily and contributes to the pathogenesis of Crohn's disease (CD) by stimulating T-helper (Th) 1 cells. In addition to Th1, recent studies have focused on the role of Th17 cells in the pathogenesis of CD. Here we tried to clarify the role of TL1A in Th1 and Th17 immunity in CD.TL1A expression was assessed by quantitative reverse-transcription polymerase chain reaction (RT-PCR) in lamina propria (LP) macrophages (LP-M[phis]s) from normal controls (NC) and patients with CD or ulcerative colitis (UC). Purified LP CD4+ T cells were stimulated with TL1A and/or IL-23 and interferon gamma (IFN-[gamma]) and interleukin (IL)-17 levels were analyzed. We also examined the effect of TL1A on naïve CD4+ T-cell differentiati...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896440</comments>
            <pubDate>Thu, 15 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2896440</guid>        </item>
        <item>
            <title>Clustering and commonalities among autoimmune diseases.</title>
            <link>http://www.medworm.com/index.php?rid=2913105&amp;cid=c_1_3_f&amp;fid=33858&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19837564%26dopt%3DAbstract</link>
            <description>Authors: Mackay IR
    The concept that autoimmune diseases are characterized by shared (common) threads is well illustrated by their propensity to co-associate in a patient or direct relatives, as coexistences or overlaps. Recognized are two major autoimmune clusters, &quot;thyrogastric&quot; (mostly organ-specific) and &quot;lupus-associated&quot; (mostly multisystem). Additionally, some autoimmune diseases distribute within either cluster and a few appear not to associate. Also, within each cluster there are overlaps constituting virtually a distinct syndrome. These patterns of coexistence/overlaps depend predominantly on genetic determinants as judged by data accruing from numerous highly powered genome-wide association studies. Gene polymorphisms thus revealed include those that may determine tissue targ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Journal of Autoimmunity</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2913105</comments>
            <pubDate>Thu, 15 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2913105</guid>        </item>
        <item>
            <title>Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity</title>
            <link>http://www.medworm.com/index.php?rid=2896409&amp;cid=c_1_17_f&amp;fid=30381&amp;url=http%3A%2F%2Fgut.bmj.com%2Fcgi%2Fcontent%2Fshort%2F58%2F11%2F1498%3Frss%3D1</link>
            <description>Conclusions:
Random biopsy surveillance is sufficiently sensitive to detect large dysplastic fields with significant colorectal cancer risk. Enhanced endoscopy can detect much smaller dysplastic fields, but these have unknown (perhaps much lower) colorectal cancer risk. Small dysplastic fields should not be assumed to indicate a high colorectal cancer risk that warrants colectomy. Prospective studies are needed to define the colorectal cancer risk and optimal management of small dysplastic lesions. (Source: Gut)</description>
            <author>Gut</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896409</comments>
            <pubDate>Thu, 15 Oct 2009 22:22:00 +0100</pubDate>
            <guid isPermaLink="false">2896409</guid>        </item>
        <item>
            <title>Aldehyde Dehydrogenase-Expressing Colon Stem Cells Contribute to Tumorigenesis in the Transition from Colitis to Cancer</title>
            <link>http://www.medworm.com/index.php?rid=2895814&amp;cid=c_1_6_f&amp;fid=33679&amp;url=http%3A%2F%2Fcancerres.aacrjournals.org%2Fcgi%2Fcontent%2Fshort%2F69%2F20%2F8208%3Frss%3D1</link>
            <description>Patients with chronic ulcerative colitis are at increased risk of developing colorectal cancer. Although current hypotheses suggest that sporadic colorectal cancer is due to inability to control cancer stem cells, the cancer stem cell hypothesis has not yet been validated in colitis-associated cancer. Furthermore, the identification of the colitis to cancer transition is challenging. We recently showed that epithelial cells with the increased expression of aldehyde dehydrogenase in sporadic colon cancer correlate closely with tumor-initiating ability. We sought to determine whether ALDH can be used as a marker to isolate tumor-initiating populations from patients with chronic ulcerative colitis. We used fluorescence-activated cell sorting to identify precursor colon cancer stem cells from ...</description>
            <author>Cancer Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2895814</comments>
            <pubDate>Thu, 15 Oct 2009 04:07:39 +0100</pubDate>
            <guid isPermaLink="false">2895814</guid>        </item>
        <item>
            <title>Biomedical Research Centre searches for immunological biomarkers</title>
            <link>http://www.medworm.com/index.php?rid=2892733&amp;cid=c_1_46_f&amp;fid=31011&amp;url=http%3A%2F%2Fwww.eurekalert.org%2Fpub_releases%2F2009-10%2Fkcl-brc101509.php</link>
            <description>(King's College London) Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and others. A group of London-based researchers hope that they will be able to identify biomarkers in the tissue and blood, which in future could be used to diagnose these conditions, to predict how they will develop and how an individual will respond to treatment. (Source: EurekAlert! - Medicine and Health)</description>
            <author>EurekAlert! - Medicine and Health</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2892733</comments>
            <pubDate>Thu, 15 Oct 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2892733</guid>        </item>
        <item>
            <title>Quality of Life Improvements Attributed to Combination Therapy with Oral and Topical Mesalazine in Mild-to-Moderately Active Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2896438&amp;cid=c_1_17_f&amp;fid=33520&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D235916</link>
            <description>Digestion 2009;80:241-246 (DOI:10.1159/000235916) (Source: Digestion)</description>
            <author>Digestion</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896438</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2896438</guid>        </item>
        <item>
            <title>Inflammatory bowel disease in young people: The case for transitional clinics</title>
            <link>http://www.medworm.com/index.php?rid=2896443&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21145</link>
            <description>The incidence of inflammatory bowel disease (IBD) is increasing among adolescents. In all, 25% of patients are diagnosed before the age of 16, when they are traditionally transferred from the pediatric to the adult service.We conducted a retrospective case-controlled study to characterize patients treated in a novel transitional adolescent-young adult IBD clinic. This compared disease extent, radiation exposure, therapeutic strategy, and requirement for surgery in 100 adolescents with controls from our adult IBD clinic matched for disease duration.The median (range) ages for the adolescent and adult population was 19 (16-28) and 43 (24-84), with a median age at diagnosis of 15 (3-26) and 39 (13-82) respectively (P &lt; 0.001). Crohn's disease was significantly more common in the adolescents. ...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896443</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2896443</guid>        </item>
        <item>
            <title>Genome-wide gene expression analysis of mucosal colonic biopsies and isolated colonocytes suggests a continuous inflammatory state in the lamina propria of patients with quiescent ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2896444&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21142</link>
            <description>This study has demonstrated the presence of a continuous inflammatory state in quiescent UC, which seems to reflect an altered gene expression profile of lamina propria cells. Inflamm Bowel Dis 2009 (Source: Inflammatory Bowel Diseases)</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896444</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2896444</guid>        </item>
        <item>
            <title>Infliximab therapy for patients with inflammatory bowel disease: 10 years on.</title>
            <link>http://www.medworm.com/index.php?rid=2905574&amp;cid=c_1_13_f&amp;fid=35551&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19837056%26dopt%3DAbstract</link>
            <description>Authors: Van Assche G, Vermeire S, Rutgeerts P
    The advent of infliximab a decade ago has drastically changed the treatment paradigm for patients with inflammatory bowel diseases (IBD). Controlled evidence supports the use of this anti TNF antibody to treat luminal and fistulizing Crohn's disease, ulcerative colitis, pediatric Crohn's disease and extraintestinal manifestations of IBD. For all IBD indications induction with infliximab 5mg/kg IV at week 0-2-6, followed by q 8weeks scheduled maintenance is advocated. Novel treatment goals such as mucosal healing and the reduction of hospitalizations and surgeries, have been achieved by infliximab and open the perspective of disease modification. The benefit to risk ratio of infliximab is comparable to that of other immunosuppressive treatm...</description>
            <author>European Journal of Pharmacology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905574</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2905574</guid>        </item>
        <item>
            <title>Ten years of infliximab (Remicade(R)) in clinical practice: The story from bench to bedside.</title>
            <link>http://www.medworm.com/index.php?rid=2905576&amp;cid=c_1_13_f&amp;fid=35551&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19837054%26dopt%3DAbstract</link>
            <description>Authors: Cornillie F
    Infliximab was first introduced in Europe in 1999 for Crohn's disease. During the following decade major progress was made in the understanding of the pathophysiology of inflammatory bowel diseases and treatment with infliximab. Today, treatment algorithms with anti-TNF and optimization of anti-TNF use in daily clinical practice are important research topics in Crohn's disease and ulcerative colitis. TNF blockade has also changed the rheumatology practice during the last 10 years. Earlier treatment, combination with disease modifying antirheumatic drugs, and identification of risk factors of poor prognosis are hot research topics today. The introduction of infliximab (among other biological therapies) has thus changed the way how inflammatory bowel diseases and rhe...</description>
            <author>European Journal of Pharmacology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905576</comments>
            <pubDate>Wed, 14 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2905576</guid>        </item>
        <item>
            <title>Infliximab Linked to Lower Colectomy Rates in Moderate to Severe Active Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2891223&amp;cid=c_1_26_f&amp;fid=23294&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F710500%3Fsrc%3Drss</link>
            <description>In randomized controlled trials, patients treated with infliximab for moderately to severely active ulcerative colitis were less likely to undergo colectomy through 54 weeks vs those receiving placebo.  Medscape Medical News (Source: Medscape Medical News Headlines)</description>
            <author>Medscape Medical News Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2891223</comments>
            <pubDate>Wed, 14 Oct 2009 16:59:05 +0100</pubDate>
            <guid isPermaLink="false">2891223</guid>        </item>
        <item>
            <title>Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease</title>
            <link>http://www.medworm.com/index.php?rid=2896432&amp;cid=c_1_17_f&amp;fid=33434&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8717208l72851646%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;The results evidenced that low sensitivity of ASCA and pANCA markers limits their use in IBD screening in the general population;
 however, their specificity may contribute to differentiation between CD and UC in IBD patients. Our study lends further support
 to the suggestion that serologic assessment identifies different subtypes of IBD.
 
 
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10620-009-0998-7Authors
		Renato Mitsunori Nisihara, Federal University of Paraná Laboratory of Immunopathology Rua João Azolin, 660 Curitiba PR 82015-040 BrazilWilson Beleski de Carvalho, Federal University of Paraná Department of Gastroenterology Curitiba PR BrazilShirley Ramos da Rosa Utiyama, Federal University of Paraná Laboratory of Immunopathology R...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Digestive Diseases and Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2896432</comments>
            <pubDate>Wed, 14 Oct 2009 05:58:13 +0100</pubDate>
            <guid isPermaLink="false">2896432</guid>        </item>
        <item>
            <title>PSC Partners Seeking a Cure: Request for Proposals--Primary Sclerosing Cholangitis</title>
            <link>http://www.medworm.com/index.php?rid=2893081&amp;cid=c_1_39_f&amp;fid=38202&amp;url=http%3A%2F%2Fwww.scangrants.com%2F</link>
            <description>The PSC Partners Seeking a Cure Foundation is a non-profit 501(c)3 foundation whose mission is to provide research, education, and support for people affected by Primary Sclerosing Cholangitis (PSC). The PSC Partners Seeking a Cure Foundation offers grants to support PSC researchers to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely allied diseases, such as inflammatory bowel diseases (IBD) (ulcerative colitis (UC) or Crohn's disease). The applicant must be at an academic institution. The goal of funding is to help encourage investigators to conduct research in a promising new area. Funding is limited to $20,000 per year for 2 years ($40,000 total). The PSC Partners Seeking a Cure Foundation is particularly interested ...</description>
            <author>ScanGrants feed</author>
            <type>funding</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2893081</comments>
            <pubDate>Tue, 13 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2893081</guid>        </item>
        <item>
            <title>Natalizumab: Ocular herpes zoster, or bacterial infections leading to ulcerative colitis or abscess: 3 case reports</title>
            <link>http://www.medworm.com/index.php?rid=2881810&amp;cid=c_1_13_f&amp;fid=33942&amp;url=http%3A%2F%2Fwww.ingentaconnect.com%2Fcontent%2Fadis%2Frea%2F2009%2F00000001%2F00001273%2Fart00079</link>
            <description>(Source: Reactions)</description>
            <author>Reactions</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2881810</comments>
            <pubDate>Mon, 12 Oct 2009 13:02:30 +0100</pubDate>
            <guid isPermaLink="false">2881810</guid>        </item>
        <item>
            <title>Ulcerative colitis in a Southern European country: A national perspective</title>
            <link>http://www.medworm.com/index.php?rid=2884188&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21119</link>
            <description>The incidence, prevalence, and even the clinical behavior of ulcerative colitis (UC) are highly variable in different world regions. In previous studies, Portugal was reported as having a milder clinical behavior. The aim of this study was to apply the Montreal Classification in a large group of UC Portuguese patients in order to describe their clinical characteristics and evaluate variables potentially useful for outcome prediction.A cross-sectional study based on data collected from a nationwide online registry was undertaken.In all, 2863 patients with UC were included. Twenty-one percent had ulcerative proctitis, 52% left-sided colitis, and 28% extensive colitis. Sixty percent of patients had taken steroids, 14% immunosuppressors, 1% biologicals, and 4.5% were submitted to surgery. Pati...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2884188</comments>
            <pubDate>Sun, 11 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2884188</guid>        </item>
        <item>
            <title>Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease</title>
            <link>http://www.medworm.com/index.php?rid=2884189&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21113</link>
            <description>We describe the incidence and outcome of CTE in pediatric IBD patients from a single center over 5 years and the relative proportion of stroke reported in the literature in patients with UC and CD before and after January 2000.Demographic data were extracted on all newly diagnosed cases of IBD in our center from January 2003 to January 2008 to ascertain patient characteristics, disease type, risk factors for CTE, modality of neuroimaging, and outcome. A literature search was performed to identify all articles describing stroke in pediatric IBD. All identified studies were stratified into those published before and after January 1 2000.In all, 154 new patients diagnosed with IBD (male 56%) (UC 30%, CD 64%, IBD unclassified [IBDU] 6%) were reviewed. Four cases of CTE occurred in our populati...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2884189</comments>
            <pubDate>Sun, 11 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2884189</guid>        </item>
        <item>
            <title>Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease</title>
            <link>http://www.medworm.com/index.php?rid=2884190&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21052</link>
            <description>Crohn's disease (CD) is a multifactorial syndrome with genetic and environmental contributions. Mycobacterium avium subspecies paratuberculosis (MAP) has been frequently isolated from mucosal tissues of patients with CD but the cellular immune response to this bacterium has been poorly described. Our aim was to examine the influence of MAP on T-cell proliferation and cytokine responses in patients with inflammatory bowel disease (IBD).Peripheral blood mononuclear cells (PBMCs) and mesenteric lymph node cells (MLNCs) were obtained from IBD patients and non-IBD controls. PBMC T-cell proliferation in response to MAP was determined using CFSE labeling and flow cytometry. The specificity of cytokine responses to MAP was controlled by parallel exposure to Listeria monocytogenes (LM) or Salmonell...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2884190</comments>
            <pubDate>Sun, 11 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2884190</guid>        </item>
        <item>
            <title>Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis.</title>
            <link>http://www.medworm.com/index.php?rid=2891877&amp;cid=c_1_39_f&amp;fid=38062&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822631%26dopt%3DAbstract</link>
            <description>CONCLUSIONS: To the best of our knowledge, our trial will be the first randomized controlled trial to evaluate telemedicine in subjects with gastrointestinal disease. We describe several issues encountered in design and implementation of our trial that will aid investigators when planning telemedicine trials in inflammatory bowel disease.
    PMID: 19822631 [PubMed - as supplied by publisher] (Source: Clinical Trials)</description>
            <author>Clinical Trials</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2891877</comments>
            <pubDate>Sun, 11 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2891877</guid>        </item>
        <item>
            <title>Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic &amp; ulcerative colitis.</title>
            <link>http://www.medworm.com/index.php?rid=2902034&amp;cid=c_1_59_f&amp;fid=34410&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833115%26dopt%3DAbstract</link>
            <description>CONCLUSIONS: A significant association was observed between alpha2A-1291C&amp;gt;G polymorphism and D-IBS. Thus, alpha2 AR gene may be a potential candidate involved in pathophysiology of D-IBS.
    PMID: 19833115 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Chemistry)</description>
            <author>International Journal of Clinical Chemistry</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2902034</comments>
            <pubDate>Sun, 11 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2902034</guid>        </item>
        <item>
            <title>Effect of Wumeiwan on cytokines TNF-α, IL-6, IL-8, IL-10 and expression of NF-κBp65 in rats with ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2889147&amp;cid=c_1_39_f&amp;fid=35989&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp7w5x4nj2m4733h4%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;The effects of Wumeiwan (WMW) on TNF-α, IL-6, IL-8, IL-10 and NF-κBp65 in rats with ulcerative colitis (UC) were investigated,
 the curative effectiveness of WMW vs salicylazosulfapyridine (SASP) was compared, and the action mechanism was analyzed. Fifty-Six
 Sprague-Dawley (SD) rats were randomly divided into four groups (n=14 in each group, with equal ratio of male and female): normal control group, model group, SASP group, and WMW group. Except
 normal control group, the rat UC models in the remaining three groups were established using the method of 2.4-dinitrochlorobenzene
 (DNCB) immunization and acetic acid local enema. The rats in model group, SASP group, and WMW group were treated with distilled
 water, SASP, and WMW respectively. The changes in the symptoms a...</description>
            <author>Journal of Huazhong University of Science and Technology -- Medical Sciences --</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2889147</comments>
            <pubDate>Sun, 11 Oct 2009 07:02:54 +0100</pubDate>
            <guid isPermaLink="false">2889147</guid>        </item>
        <item>
            <title>How can we really reduce the morbidity of inflammatory bowel disease — Research on genes and cytokines, or find out the causative factors in the environment?</title>
            <link>http://www.medworm.com/index.php?rid=2968839&amp;cid=c_1_17_f&amp;fid=38417&amp;url=http%3A%2F%2Fwww.ecco-jccjournal.org%2Farticle%2FPIIS187399460900097X%2Fabstract%3Frss%3Dyes</link>
            <description>Dear Sir,  Right now, millions of patients all over the world are suffering from the devastating inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), both of which have very high incidences in children and adolescence and are still regarded as incurable. Currently, the main efforts of research on IBD remain largely on genes, cytokines, and other cellular and molecular changes, with the utmost finding by the recent genome-wide association study that more than 30 distinct susceptibility loci are associated with CD. It revealed the complex in the pathogenesis of IBD. However, all these genes together have been estimated only account for about 10% of the variety in the risk of CD. The weak contribution by each gene, along with the non-specific nature of ...</description>
            <author>Journal of Critical Care</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2968839</comments>
            <pubDate>Fri, 09 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2968839</guid>        </item>
        <item>
            <title>Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2877734&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21121</link>
            <description>No abstract. (Source: Inflammatory Bowel Diseases)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2877734</comments>
            <pubDate>Thu, 08 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2877734</guid>        </item>
        <item>
            <title>The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity</title>
            <link>http://www.medworm.com/index.php?rid=2877736&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21112</link>
            <description>Individuals with ulcerative colitis are at high risk of developing colitis-associated cancer. 5-Aminosalicylate (5-ASA) protects from cancer by its antiinflammatory activity as well as by altering cell growth, inducing apoptosis, and reducing replication errors. So far neither 5-ASA's structural specificity nor its pharmacophore group have been identified. Here we compared 5-ASA with its analogs (4-ASA and 3-ASA) and its metabolite N-acetyl-5-ASA (NAc-5-ASA).Superoxide scavenging was analyzed by lucigenin-amplified chemiluminescence. Cell growth, cell cycle distribution, and replication fidelity at a (CA)13 microsatellite were measured in HCT116 and HT29 colon epithelial cells by MTT and flow cytometry. Nuclear protein extracts were blotted for replication protein A (RPA), claspin, p53, an...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2877736</comments>
            <pubDate>Thu, 08 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2877736</guid>        </item>
        <item>
            <title>Comparison of colectomy rate after treatment of ulcerative colitis with placebo or infliximab</title>
            <link>http://www.medworm.com/index.php?rid=2873512&amp;cid=c_1_13_f&amp;fid=38936&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FNews%2F2009---October%2F08%2FComparison-of-colectomy-rate-after-treatment-of-ulcerative-colitis-with-placebo-or-infliximab-%2F</link>
            <description>Source: Gastroenterology
Area: News
 An article in Gastroenterology from the investigators of the ACT-1 and ACT-2 multicentre trials, report long-term data on colectomy and hospitalisations among patients with moderate-to-severe ulcerative colitis (UC) randomised to infliximab or placebo. 
 &amp;nbsp; 
 In these studies, 728 patients received placebo or infliximab (5 or 10 mg/kg) at weeks 0, 2, and 6, then every 8 weeks through week 46 (ACT-1) or 22 (ACT-2). Colectomy, hospitalisation, and surgery/procedure data through 54 weeks after the first infusion were obtained from ACT-1, ACT-2, and associated data sources. In the pre-specified analysis, all data were combined to ascertain time to colectomy. 
 &amp;nbsp; 
 The following findings were reported: 
 &amp;nbsp; 
 .&amp;nbsp;87% (630 of 728) of patients ...</description>
            <author>NeLM - News</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2873512</comments>
            <pubDate>Wed, 07 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2873512</guid>        </item>
        <item>
            <title>Prevalence and pathogenesis of anemia in Inflammatory Bowel disease. Influence of anti-tumor necrosis factor-{alpha} treatment.</title>
            <link>http://www.medworm.com/index.php?rid=2880230&amp;cid=c_1_19_f&amp;fid=29484&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19815838%26dopt%3DAbstract</link>
            <description>Conclusions In out-patients with inflammatory bowel disease anemia is a common problem whose prevalence and severity are related to disease activity. The pathogenesis of anemia changes during the course of the disease, with ACD having a major role at diagnosis and iron deficiency and multifactorial forms of anemia during follow-up. In patients requiring anti-TNF-alpha treatment, response to therapy improves erythropoiesis.
    PMID: 19815838 [PubMed - as supplied by publisher] (Source: Haematologica)</description>
            <author>Haematologica</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2880230</comments>
            <pubDate>Wed, 07 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2880230</guid>        </item>
        <item>
            <title>Reversible posterior leukoencephalopathy syndrome in childhood: report of nine cases and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=2873922&amp;cid=c_1_25_f&amp;fid=33319&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv674mmv11n3n6h0k%2F</link>
            <description>We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis,
 idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte
 transfusion for severe iron deficiency, l-asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative
 colitis due to neutropenia. Early recognition of RPLS as complication during different diseases and therapy in childhood may
 facilitate precise diagnosis and appropriate treatment.
 
	Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10072-009-0158-zAuthors
		Hakan Gümüş, Kayseri Education and Research Hospital Department of Pediatric Neurology Talas Kayseri...</description>
            <author>Neurological Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2873922</comments>
            <pubDate>Wed, 07 Oct 2009 07:40:31 +0100</pubDate>
            <guid isPermaLink="false">2873922</guid>        </item>
        <item>
            <title>Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression [Medical_Sciences]</title>
            <link>http://www.medworm.com/index.php?rid=2868274&amp;cid=c_1_58_f&amp;fid=30174&amp;url=http%3A%2F%2Fwww.pnas.org%2Fcgi%2Fcontent%2Fshort%2F106%2F40%2F17146%3Frss%3D1</link>
            <description>Chronic inflammation and cancer are intimately associated. This is particularly true for inflammatory bowel diseases (IBD), such as ulcerative colitis... (Source: Proceedings of the National Academy of Sciences)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Proceedings of the National Academy of Sciences</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2868274</comments>
            <pubDate>Tue, 06 Oct 2009 21:23:13 +0100</pubDate>
            <guid isPermaLink="false">2868274</guid>        </item>
        <item>
            <title>Aldehyde Dehydrogenase-Expressing Colon Stem Cells Contribute to Tumorigenesis in the Transition from Colitis to Cancer.</title>
            <link>http://www.medworm.com/index.php?rid=2872682&amp;cid=c_1_171_f&amp;fid=30451&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19808966%26dopt%3DAbstract</link>
            <description>Authors: Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW, Huang EH
    Patients with chronic ulcerative colitis are at increased risk of developing colorectal cancer. Although current hypotheses suggest that sporadic colorectal cancer is due to inability to control cancer stem cells, the cancer stem cell hypothesis has not yet been validated in colitis-associated cancer. Furthermore, the identification of the colitis to cancer transition is challenging. We recently showed that epithelial cells with the increased expression of aldehyde dehydrogenase in sporadic colon cancer correlate closely with tumor-initiating ability. We sought to determine whether ALDH can be used as a marker to isolate tumor-initiating populations from patients with chronic ulcerative colitis. We...</description>
            <author>Cell Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2872682</comments>
            <pubDate>Mon, 05 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2872682</guid>        </item>
        <item>
            <title>Crohn's &amp; Colitis Foundation of America Student Research Fellowship Awards</title>
            <link>http://www.medworm.com/index.php?rid=2861197&amp;cid=c_1_39_f&amp;fid=38202&amp;url=http%3A%2F%2Fwww.scangrants.com%2F</link>
            <description>Crohn's &amp; Colitis Foundation of America Student Research Fellowship Awards
Full Online Application Due	March 15Submission of Paper Copy	Postmarked March 15Review	mid AprilStart Date	on or about June 15Final/Financial Reports	September 1Total Award: $2,500 (indirect costs are not allowed)Duration of Award: One time payment (project must last at least 10 weeks)Objective: This program offers financial support for students to spend time performing research on topics relevant to inflammatory bowel disease for a minimum of 10 weeks. CCFA hopes to stimulate research interest in the areas of Crohn's disease or ulcerative colitis.Applicant Eligibility: Candidates may be undergraduate, medical or graduate students (not yet engaged in thesis research) in accredited United States institutions. Can...</description>
            <author>ScanGrants feed</author>
            <type>funding</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2861197</comments>
            <pubDate>Sun, 04 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2861197</guid>        </item>
        <item>
            <title>Crohn's &amp; Colitis Foundation of America Career Development Awards</title>
            <link>http://www.medworm.com/index.php?rid=2861198&amp;cid=c_1_39_f&amp;fid=38202&amp;url=http%3A%2F%2Fwww.scangrants.com%2F</link>
            <description>Crohn's &amp; Colitis Foundation of America Career Development Awards
Letter of Intent to Apply Due	November 1	May 1Full Online Application Due	January 14	July 1Submission of Paper Copy	Postmarked January 14	Postmarked July 1Review	mid April	mid NovemberBoard of Trustees	mid April	mid NovemberStart Date	July 1	January 1Total Award: Up to $90,000 per yearDuration of Award: One to Three YearsObjective: Career Development Awards are offered to encourage the development of individuals with research potential to help them prepare for an career of independent basic and/or clinical investigation in the area of inflammatory bowel disease. Therefore, individuals who are already well established in the field of IBD research are not considered eligible for this award.Applicant Eligibility: Applicant ...</description>
            <author>ScanGrants feed</author>
            <type>funding</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2861198</comments>
            <pubDate>Sun, 04 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2861198</guid>        </item>
        <item>
            <title>Crohn's &amp; Colitis Foundation of America Senior Research Awards</title>
            <link>http://www.medworm.com/index.php?rid=2861200&amp;cid=c_1_39_f&amp;fid=38202&amp;url=http%3A%2F%2Fwww.scangrants.com%2F</link>
            <description>Crohn's &amp; Colitis Foundation of America Senior Research AwardsLetter of Intent to Apply Due November 1 May 1Full Online Application Due January 14 July 1Submission of Paper Copy Postmarked January 14 Postmarked July 1Review mid April mid NovemberBoard of Trustees mid April mid NovemberStart Date July 1 January 1Direct Costs: $130,000 per yearIndirect Costs: 10% of direct costs or $13,000Duration of Award: One to Three YearsObjective: To provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources, such as the National Institute of Health (NIH).Applicant Eligibility: Applicant must hold an MD, PhD, or equivalent degree and must be employed by an institution (public non-profit, private non-profit or government) enga...</description>
            <author>ScanGrants feed</author>
            <type>funding</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2861200</comments>
            <pubDate>Sun, 04 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2861200</guid>        </item>
        <item>
            <title>Crohn's &amp; Colitis Foundation of America Research Fellowship Awards</title>
            <link>http://www.medworm.com/index.php?rid=2861201&amp;cid=c_1_39_f&amp;fid=38202&amp;url=http%3A%2F%2Fwww.scangrants.com%2F</link>
            <description>Crohn's &amp; Colitis Foundation of America Research Fellowship AwardsLetter of Intent to Apply Due November 1 May 1Full Online Application Due January 14 July 1Submission of Paper Copy Postmarked January 14 Postmarked July 1Review mid April mid NovemberBoard of Trustees mid April mid NovemberStart Date July 1 January 1Total Award: Up to $58,250 per yearDuration of Award: One to Three YearsObjective: Research Fellowship Awards are offered to encourage the development of individuals with research potential to help them prepare for a career of independent basic and/or clinical investigation in the area of Crohn's disease and ulcerative colitis.Applicant Eligibility: Individuals who are already well established in the field of IBD research are not considered eligible for this award. Applicant...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>ScanGrants feed</author>
            <type>funding</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2861201</comments>
            <pubDate>Sun, 04 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2861201</guid>        </item>
        <item>
            <title>Crohn's &amp; Colitis Foundation Launches New Web Site to Commence Take Steps Walk Season: Walkers Can Take the Step that Counts Using New Interactive Features</title>
            <link>http://www.medworm.com/index.php?rid=2858285&amp;cid=c_1_34_f&amp;fid=22564&amp;url=http%3A%2F%2Fwww.prweb.com%2Freleases%2F2009%2F10%2Fprweb2984894.htm</link>
            <description>The Crohn&amp;#039;s &amp;#38; Colitis Foundation of America recently launched its updated web site to usher in the 2010 Walk season comprising of over 100 walks nationwide. The Foundation reached a new plateau with new interactive features such as a blog, downloadable banners and widgets, and tips and tools for fundraising to support the walks that raise much-needed awareness of and funds for the 1.4 million Americans living with Crohn&amp;#039;s disease and ulcerative colitis, chronic and painful digestive diseases. (PRWeb Oct 3, 2009)
    Read the full story at http://www.prweb.com/releases/2009/10/prweb2984894.htm (Source: PRWeb: Medical Pharmaceuticals)</description>
            <author>PRWeb:  Medical  Pharmaceuticals</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2858285</comments>
            <pubDate>Sun, 04 Oct 2009 17:14:36 +0100</pubDate>
            <guid isPermaLink="false">2858285</guid>        </item>
        <item>
            <title>Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half</title>
            <link>http://www.medworm.com/index.php?rid=2856874&amp;cid=c_1_34_f&amp;fid=36544&amp;url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FInfLdSjfFy8%2Fulcerative-colitis-reduces-need-surgery-almost-half-8176.html</link>
            <description>ROCHESTER, Minn., Oct. 1 /PRNewswire-USNewswire/ -- A new study
led by Mayo Clinic researchers has found that ulcerative colitis
patients had a 41 percent reduction in colectomy after a year when
treated with infliximab, according to a study... (Source: Drugs.com - Clinical Trials)</description>
            <author>Drugs.com - Clinical Trials</author>
            <type>clinical trials</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2856874</comments>
            <pubDate>Sat, 03 Oct 2009 12:47:49 +0100</pubDate>
            <guid isPermaLink="false">2856874</guid>        </item>
        <item>
            <title>Need For Surgery Almost Halved By Ulcerative Colitis Treatment</title>
            <link>http://www.medworm.com/index.php?rid=2856283&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F166022.php</link>
            <description>A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2856283</comments>
            <pubDate>Sat, 03 Oct 2009 07:00:00 +0100</pubDate>
            <guid isPermaLink="false">2856283</guid>        </item>
        <item>
            <title>Drug May Help Colitis Patients Avoid Surgery</title>
            <link>http://www.medworm.com/index.php?rid=2859653&amp;cid=c_1_26_f&amp;fid=37163&amp;url=http%3A%2F%2Fwww.nlm.nih.gov%2Fenter%2Fmedlineplus%2Frss%3Ffeed%3DTodays%2520MedlinePlus%2520Health%2520News%26url%3Dhttp%253A%252F%252Fwww%252Enlm%252Enih%252Egov%252Fmedlineplus%252Fnews%252Ffullstory%255F90137%252Ehtml</link>
            <description>Infliximab linked to fewer colectomies in study patients Source: HealthDay 
   	
    Related MedlinePlus Topics: Medicines, Ulcerative Colitis (Source: MedlinePlus Health News)</description>
            <author>MedlinePlus Health News</author>
            <type>consumer</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2859653</comments>
            <pubDate>Fri, 02 Oct 2009 18:00:00 +0100</pubDate>
            <guid isPermaLink="false">2859653</guid>        </item>
        <item>
            <title>Retinoic Acid May Alleviate Ulcerative Colitis And Similar Irritable Bowel Diseases</title>
            <link>http://www.medworm.com/index.php?rid=2852942&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F166040.php</link>
            <description>Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases. (Source: Health News from Medical News Today)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2852942</comments>
            <pubDate>Fri, 02 Oct 2009 12:00:00 +0100</pubDate>
            <guid isPermaLink="false">2852942</guid>        </item>
        <item>
            <title>Ulcerative Colitis Treatment Reduces Need for Surgery</title>
            <link>http://www.medworm.com/index.php?rid=2855475&amp;cid=c_1_179_f&amp;fid=38944&amp;url=http%3A%2F%2Fwww.disabled-world.com%2Fhealth%2Fdigestive%2Fulcerative-colitis-treatment.php</link>
            <description>A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. (Source: Disabled World)</description>
            <author>Disabled World</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2855475</comments>
            <pubDate>Thu, 01 Oct 2009 23:23:25 +0100</pubDate>
            <guid isPermaLink="false">2855475</guid>        </item>
        <item>
            <title>Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half</title>
            <link>http://www.medworm.com/index.php?rid=2852420&amp;cid=c_1_26_f&amp;fid=23292&amp;url=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F165882.php</link>
            <description>A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.  Ulcerative colitis, an inflammatory bowel disease (IBD) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. (Source: Health News from Medical News Today)</description>
            <author>Health News from Medical News Today</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2852420</comments>
            <pubDate>Thu, 01 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2852420</guid>        </item>
        <item>
            <title>Drug Tied to Lower Colectomy Rate in Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2860457&amp;cid=c_1_22_f&amp;fid=38164&amp;url=http%3A%2F%2Fwww.modernmedicine.com%2Fmodernmedicine%2FModern%2BMedicine%2BNow%2FDrug-Tied-to-Lower-Colectomy-Rate-in-Ulcerative-Co%2FArticleNewsFeed%2FArticle%2Fdetail%2F631259%3Fref%3D25</link>
            <description>In patients with moderate-to-severe ulcerative colitis, treatment with infliximab is associated with a
  significantly lower likelihood of undergoing colectomy within one year, according to a study published in the
  October Gastroenterology. (Source: Modern Medicine)</description>
            <author>Modern Medicine</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2860457</comments>
            <pubDate>Thu, 01 Oct 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2860457</guid>        </item>
        <item>
            <title>Blockade of a Chemokine, CCL2, Reduces Chronic Colitis-Associated Carcinogenesis in Mice</title>
            <link>http://www.medworm.com/index.php?rid=2853178&amp;cid=c_1_6_f&amp;fid=33679&amp;url=http%3A%2F%2Fcancerres.aacrjournals.org%2Fcgi%2Fcontent%2Fshort%2F69%2F19%2F7884%3Frss%3D1</link>
            <description>Accumulating evidence indicates the crucial contribution of chronic inflammation to various types of carcinogenesis, including colon carcinoma associated with ulcerative colitis and asbestosis-induced malignant mesothelioma. Ulcerative colitis&amp;ndash;associated colon carcinogenesis can be recapitulated in mice by azoxymethane administration followed by repetitive dextran sulfate sodium ingestion. In the course of this carcinogenesis process, the expression of a macrophage-tropic chemokine, CCL2, was enhanced together with intracolonic massive infiltration of macrophages, which were a major source of cyclooxygenase (COX)-2, a crucial mediator of colon carcinogenesis. Mice deficient in CCL2-specific receptor, CCR2, exhibited less macrophage infiltration and lower tumor numbers with attenuated...</description>
            <author>Cancer Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2853178</comments>
            <pubDate>Thu, 01 Oct 2009 18:26:06 +0100</pubDate>
            <guid isPermaLink="false">2853178</guid>        </item>
        <item>
            <title>Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests</title>
            <link>http://www.medworm.com/index.php?rid=2850507&amp;cid=c_1_58_f&amp;fid=23305&amp;url=http%3A%2F%2Ffeeds.sciencedaily.com%2F%7Er%2Fsciencedaily%2F%7E3%2FqNCr7_IfXhc%2F091001081215.htm</link>
            <description>A new study has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab. (Source: ScienceDaily Headlines)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>ScienceDaily Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2850507</comments>
            <pubDate>Thu, 01 Oct 2009 18:11:01 +0100</pubDate>
            <guid isPermaLink="false">2850507</guid>        </item>
        <item>
            <title>Oxidized Form Of A Common Vitamin May Bring Relief For Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2850520&amp;cid=c_1_58_f&amp;fid=23305&amp;url=http%3A%2F%2Ffeeds.sciencedaily.com%2F%7Er%2Fsciencedaily%2F%7E3%2FnQwjSgvaZzU%2F091001091755.htm</link>
            <description>Here's another reason why you should take your vitamins. A new research report suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases. Specifically they found that retinoic acid helps suppress out-of-control inflammation, which is a hallmark of active ulcerative colitis. (Source: ScienceDaily Headlines)</description>
            <author>ScienceDaily Headlines</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2850520</comments>
            <pubDate>Thu, 01 Oct 2009 18:11:01 +0100</pubDate>
            <guid isPermaLink="false">2850520</guid>        </item>
        <item>
            <title>Management of Acute Severe Ulcerative Colitis</title>
            <link>http://www.medworm.com/index.php?rid=2854268&amp;cid=c_1_43_f&amp;fid=32970&amp;url=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F708925%3Fsrc%3Drss</link>
            <description>UC is a chronic relapsing and remitting inflammatory disorder usually managed successfully with maintenance oral medications. However, some patients require rescue medical therapy or surgery.  Expert Review of Gastroenterology and Hepatology (Source: Medscape General Surgery Headlines)</description>
            <author>Medscape General Surgery Headlines</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2854268</comments>
            <pubDate>Thu, 01 Oct 2009 16:30:57 +0100</pubDate>
            <guid isPermaLink="false">2854268</guid>        </item>
        <item>
            <title>Infliximab Lowers Risk of Colectomy in Ulcerative Colitis (CME/CE)</title>
            <link>http://www.medworm.com/index.php?rid=2848415&amp;cid=c_1_17_f&amp;fid=30405&amp;url=http%3A%2F%2Fwww.medpagetoday.com%2FGastroenterology%2FInflammatoryBowelDisease%2F16222</link>
            <description>Treatment of moderate-to-severe ulcerative colitis with infliximab appears to reduce the need for colectomy, according to an analysis of data from two double-blind studies. (Source: MedPage Today Gastroenterology)</description>
            <author>MedPage Today Gastroenterology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2848415</comments>
            <pubDate>Thu, 01 Oct 2009 13:02:11 +0100</pubDate>
            <guid isPermaLink="false">2848415</guid>        </item>
        <item>
            <title>Infliximab reduces need for surgery in ulcerative colitits</title>
            <link>http://www.medworm.com/index.php?rid=2847488&amp;cid=c_1_26_f&amp;fid=35287&amp;url=http%3A%2F%2Fmedicineworld.org%2Fstories%2Flead%2F10-2009%2Finfliximab-reduces-need-for-surgery.html</link>
            <description>A newly released study led by Mayo Clinic scientists has observed that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, as per a research studyreported in the October 2009 issue of Gastroenterology. Typically ulcerative colitis, an inflammatory bowel disease (ibd) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. Like Crohn's disease, another common IBD, ulcerative colitis can be debilitating and often lead to colectomy or surgical removal of the colon........ (Source: Medicineworld.org: New Article Alert)</description>
            <author>Medicineworld.org: New Article Alert</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2847488</comments>
            <pubDate>Thu, 01 Oct 2009 12:43:47 +0100</pubDate>
            <guid isPermaLink="false">2847488</guid>        </item>
        <item>
            <title>Ulcerative colitis treatment reduces need for surgery by almost half</title>
            <link>http://www.medworm.com/index.php?rid=2847266&amp;cid=c_1_46_f&amp;fid=31011&amp;url=http%3A%2F%2Fwww.eurekalert.org%2Fpub_releases%2F2009-10%2Fmc-uct092809.php</link>
            <description>(Mayo Clinic) A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. (Source: EurekAlert! - Medicine and Health)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>EurekAlert! - Medicine and Health</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2847266</comments>
            <pubDate>Thu, 01 Oct 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2847266</guid>        </item>
        <item>
            <title>Oxidized form of a common vitamin may bring relief for ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2847541&amp;cid=c_1_46_f&amp;fid=31011&amp;url=http%3A%2F%2Fwww.eurekalert.org%2Fpub_releases%2F2009-10%2Ffoas-ofo100109.php</link>
            <description>(Federation of American Societies for Experimental Biology) Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases. Specifically they found that retinoic acid helps suppress out-of-control inflammation, which is a hallmark of active ulcerative colitis. (Source: EurekAlert! - Medicine and Health)</description>
            <author>EurekAlert! - Medicine and Health</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2847541</comments>
            <pubDate>Thu, 01 Oct 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2847541</guid>        </item>
        <item>
            <title>Is Ulcerative Colitis Proctitis Associated With an Increased Risk of Colorectal Cancer?</title>
            <link>http://www.medworm.com/index.php?rid=2928828&amp;cid=c_1_17_f&amp;fid=35582&amp;url=http%3A%2F%2Fwww.gastrojournal.org%2Farticle%2FPIIS0016508509015649%2Fabstract%3Frss%3Dyes</link>
            <description>We read with great interest the article by Söderlund et al evaluating cancer occurrence and mortality in a population-based study from Sweden including 7,607 patients with ulcerative colitis (UC) or Crohn's disease (CD) who were diagnosed from 1954 to 1989. Data on colorectal cancer (CRC) were available through 2004. The authors demonstrated that over the past 35 years the risk of death from CRC declined markedly within the inflammatory bowel disease cohort. (Source: Gastroenterology)</description>
            <author>Gastroenterology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2928828</comments>
            <pubDate>Thu, 01 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2928828</guid>        </item>
        <item>
            <title>Microscopic colitis: a review for the surgical endoscopist.</title>
            <link>http://www.medworm.com/index.php?rid=2947541&amp;cid=c_1_43_f&amp;fid=32941&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19865548%26dopt%3DAbstract</link>
            <description>Authors: Datta I, Brar SS, Andrews CN, Dupre M, Ball CG, Buie WD, Beck PL
    Microscopic colitis (MC) is an inflammatory condition of the colon distinct from Crohn disease or ulcerative colitis that can cause chronic diarrhea as well as cramping and bloating. Although it was first described 30 years ago, awareness of this entity as a cause of diarrhea has only become more widespread recently. Up to 20% of adults with chronic diarrhea who have an endoscopically normal colonoscopy may have MC. Endoscopic and radiological examinations are usually normal, but histology reveals increased lymphocytes in the colonic mucosa, which typically cause watery nonbloody diarrhea. Treatment is initially supportive but can include corticosteroids and immunomodulatory therapy for resistant cases. Since sur...</description>
            <author>Canadian Journal of Surgery</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947541</comments>
            <pubDate>Thu, 01 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2947541</guid>        </item>
        <item>
            <title>Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?</title>
            <link>http://www.medworm.com/index.php?rid=2967693&amp;cid=c_1_43_f&amp;fid=37413&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19886148%26dopt%3DAbstract</link>
            <description>Authors: Cannom RR, Kaiser AM, Ault GT, Beart RW, Etzioni DA
    The treatment costs for patients in the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-alpha has been extensively used to treat IBD, with 390,000 IBD patients receiving the drug since its FDA approval in 1998. We sought to determine the impact of infliximab on population-based rates of hospitalizations and surgical care for patients with IBD in the United States. We used data from the Nationwide Inpatient Sample to analyze patterns of hospital-based treatment provided to patients with IBD between 1998 and 2005. Data from this analysis were combined with census data to calculate trends in population-based rates of treatment. Overall rates of...</description>
            <author>The American Surgeon</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2967693</comments>
            <pubDate>Thu, 01 Oct 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2967693</guid>        </item>
        <item>
            <title>Relationships between inflammatory bowel disease and perinatal factors: Both maternal and paternal disease are related to preterm birth of offspring</title>
            <link>http://www.medworm.com/index.php?rid=2848495&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21120</link>
            <description>The aims of this study were to explore the influences of familial, maternal, and paternal inflammatory disease (IBD) on perinatal outcomes in the offspring and the risk for development of IBD related to perinatal factors.Eighty-five patients with Crohn's disease (CD) and 86 with ulcerative colitis (UC) were included from a population-based incidence study enrolled 1990-1994. Family and birth records of these patients, as well as of their 207 infants, were drawn from the Norwegian Medical Birth Registry, established in 1967, and compared with the national birth cohort from the same period.Maternal (odds ratio [OR] = 2.15, 95% confidence interval [CI]: 1.36, 3.39) and paternal IBD (OR = 3.02, 95% CI: 1.82, 5.01) influenced the risk of preterm birth ( (Source: Inflammatory Bowel Diseases)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2848495</comments>
            <pubDate>Wed, 30 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2848495</guid>        </item>
        <item>
            <title>[A case of renal vein thrombosis in a patient with ulcerative colitis.]</title>
            <link>http://www.medworm.com/index.php?rid=2913345&amp;cid=c_1_17_f&amp;fid=30411&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19844145%26dopt%3DAbstract</link>
            <description>Authors: Yang DJ, Park YS, Yu YH, Jo YJ, Kim SH, Jung YY, Hwang YH, Jun DW
    Venous thrombosis and thromboembolism appear to occur more often in patient with inflammatory bowel disease (IBD). The cause of thrombotic complications in IBD is generally considered to be associated with hypercoagulable conditions. Its prevalence rate ranges from 1% to 8% in clinical studies and rises to 39% in autopsy, but the renal vein thrombosis is very rare complication in ulcerative colitis patient. A 24-year-old man presented with intermittent abdominal pain and hematochezia for 6 months and recently developed pitting edema for few weeks. He was diagnosed as severe ulcerative colitis involving whole colon combined with thrombosis in both renal veins by colonoscopy and computed tomography scan of abdomen...</description>
            <author>Korean J Gastroenter...</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2913345</comments>
            <pubDate>Wed, 30 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2913345</guid>        </item>
        <item>
            <title>Leukocyte apheresis in the management of ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2844404&amp;cid=c_1_17_f&amp;fid=36571&amp;url=http%3A%2F%2Fwww.saudijgastro.com%2Farticle.asp%3Fissn%3D1319-3767%3Byear%3D2009%3Bvolume%3D15%3Bissue%3D4%3Bspage%3D283%3Bepage%3D287%3Baulast%3DHelmy</link>
            <description>Helmy Ahmed, Abdulla Maheeba, Kagevi Ingvar, Al Kahtani KhalidSaudi Journal of Gastroenterology 2009 15(4):283-287Ulcerative colitis is a chronic inflammatory disease that affects the colon and rectum. Its pathogenesis is probably multifactorial including the influx of certain cytokines into the colonic mucosa, causing disease activity and relapse. The hypothesis of removing such cytokines from the circulation by leukocytapheresis was implemented to reduce disease activity, maintain remission, and prevent relapse. Many recent reports not only in Japan, but also in the West, have highlighted its beneficial effects in both adult and pediatric patients. Large placebo-controlled studies are needed to confirm the available data in this regard. In this article, we shed some light on the use of l...</description>
            <author>The Saudi Journal of Gastroenterology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2844404</comments>
            <pubDate>Wed, 30 Sep 2009 16:41:39 +0100</pubDate>
            <guid isPermaLink="false">2844404</guid>        </item>
        <item>
            <title>Mitogen activated protein kinases: a role in inflammatory bowel disease?</title>
            <link>http://www.medworm.com/index.php?rid=2847833&amp;cid=c_1_3_f&amp;fid=33580&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2249.2009.04033.x</link>
            <description>Since their discovery more than 15 years ago, the mitogen activated protein kinases (MAPK) have been implicated in an ever-increasingly diverse array of pathways, including inflammatory signalling cascades. Inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, are characterized by the perpetual production of inflammatory mediators. Research into the transduction pathway behind this over-production has highlighted the potential mediating role for the MAPKs and their related signalling components. This review highlights some of the research into the role for the MAPKs and their related signalling proteins in influencing the progression of IBD. (Source: Clinical and Experimental Immunology)</description>
            <author>Clinical and Experimental Immunology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2847833</comments>
            <pubDate>Tue, 29 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2847833</guid>        </item>
        <item>
            <title>Inflammatory bowel disease, gut bacteria and probiotic therapy.</title>
            <link>http://www.medworm.com/index.php?rid=2866019&amp;cid=c_1_77_f&amp;fid=35664&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19800289%26dopt%3DAbstract</link>
            <description>Authors: Reiff C, Kelly D
    Crohn's disease (CD) and ulcerative colitis (UC) are the two major forms of inflammatory bowel disease (IBD) and both diseases lead to high morbidity and health care costs. Complex interactions between the immune system, enteric commensal bacteria and host genotype are thought to underlie the development of IBD although the precise aetiology of this group of diseases is still unknown. The understanding of the composition and complexity of the normal gut microbiota has been greatly aided by the use of molecular methods and is likely to be further increased with the advent of metagenomics and metatranscriptomics approaches, which will allow an increasingly more holistic assessment of the microbiome with respect to both diversity and function of the commensal gut...</description>
            <author>International Journal of Medical Microbiology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2866019</comments>
            <pubDate>Tue, 29 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2866019</guid>        </item>
        <item>
            <title>Appendix in ulcerative colitis: significant involvement and pathogenesis</title>
            <link>http://www.medworm.com/index.php?rid=2840286&amp;cid=c_1_17_f&amp;fid=38477&amp;url=http%3A%2F%2Fwww.giejournal.org%2Farticle%2FPIIS0016510709003447%2Fabstract%3Frss%3Dyes</link>
            <description>To the Editor:  We read with interest the article by Dendrinos et al describing diffuse inflammation in the rectum and patchy inflammation in the cecum surrounding the appendiceal orifice in ulcerative colitis (UC). Although biopsy specimens from the rectum and appendiceal orifice showed cryptitis with gland branching, those from the transverse colon were normal. The authors therefore made the diagnosis of distal UC with a cecal patch. We believe that appendiceal involvement of UC, “ulcerative appendicitis,” and its pathogenesis should be highlighted. (Source: Gastrointestinal Endoscopy)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Gastrointestinal Endoscopy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2840286</comments>
            <pubDate>Tue, 29 Sep 2009 16:42:53 +0100</pubDate>
            <guid isPermaLink="false">2840286</guid>        </item>
        <item>
            <title>Cavernous transformation of the portal vein</title>
            <link>http://www.medworm.com/index.php?rid=2837866&amp;cid=c_1_37_f&amp;fid=38011&amp;url=http%3A%2F%2Fwww.PedRad.info%2F%3Fsearch%3D20020116092119</link>
            <description>17 year-old male. Unspecific immune defect with multiple organ manifestations (juvenile chronic arthritis, factor V mutation, ulcerative colitis, autoimmune hepatitis, retarded growth, celiac disease... (Source: Pediatric Radiology RSS News, Cases, Teaching Files and Publications)</description>
            <author>Pediatric Radiology RSS News, Cases, Teaching Files and Publications</author>
            <type>info</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2837866</comments>
            <pubDate>Mon, 28 Sep 2009 17:34:31 +0100</pubDate>
            <guid isPermaLink="false">2837866</guid>        </item>
        <item>
            <title>Quality of life in the late follow-up of ulcerative colitis patients submitted to restorative proctocolectomy with sphincter preservation over ten years ago</title>
            <link>http://www.medworm.com/index.php?rid=2830101&amp;cid=c_1_22_f&amp;fid=37426&amp;url=http%3A%2F%2Fwww.scielo.br%2Fscielo.php%3Fscript%3Dsci_arttext%26pid%3DS1807-59322009000900008%26lng%3Den%26nrm%3Diso%26tlng%3Den</link>
            <description>CONCLUSION: We can conclude that the possibility of sphincter preservation should always be taken into account, since patients remain clinically stable and have a high quality of life even after long periods. (Source: Clinics)</description>
            <author>Clinics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2830101</comments>
            <pubDate>Fri, 25 Sep 2009 16:42:40 +0100</pubDate>
            <guid isPermaLink="false">2830101</guid>        </item>
        <item>
            <title>An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements</title>
            <link>http://www.medworm.com/index.php?rid=2949194&amp;cid=c_1_13_f&amp;fid=32539&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2009.04152.x</link>
            <description>Conclusions Our observations confirm the difficulty of accurately assessing medication adherence. Nonmodifiable (younger age, South Asian ethnicity) and potentially modifiable (medication beliefs) predictors of non-adherence were identified. (Source: Alimentary Pharmacology and Therapeutics)</description>
            <author>Alimentary Pharmacology and Therapeutics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2949194</comments>
            <pubDate>Thu, 24 Sep 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2949194</guid>        </item>
        <item>
            <title>Mucosal remodeling in long-standing ulcerative colitis with colorectal neoplasia: Significant alterations of NCAM+ or &amp;#x03B1;-SMA+ subepithelial myofibroblasts and interstitial cells</title>
            <link>http://www.medworm.com/index.php?rid=2826682&amp;cid=c_1_32_f&amp;fid=28435&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1440-1827.2009.02432.x</link>
            <description>Evidence has been provided in ulcerative colitis (UC) that early genomic instability of both epithelial and stromal cells is important for colorectal tumorigenesis, as well as remodeling and morphological alterations of mucosal crypts. To clarify roles of stromal cells in tumor development in UC, the present study focused on heterogeneous phenotypes of subepithelial myofibroblasts and interstitial cells, in association with mucosal remodeling. To clarify the relationship of alterations to tumorigenesis, mucosa of resected rectae from patients with UC (n= 49) and sporadic cancer (n= 10) were analyzed on immunohistochemistry and also on immunoelectron microscopy. Heterogeneous phenotypes of neural cell adhesion molecule (NCAM)+ and/or [alpha]-smooth muscle actin ([alpha]-SMA)+ subepithelial ...</description>
            <author>Pathology International</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2826682</comments>
            <pubDate>Wed, 23 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2826682</guid>        </item>
        <item>
            <title>Surgery in Ulcerative Colitis: Indication and Timing</title>
            <link>http://www.medworm.com/index.php?rid=2833327&amp;cid=c_1_17_f&amp;fid=33521&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D228570</link>
            <description>Dig Dis 2009;27:335-340 (DOI:10.1159/000228570) (Source: Digestive Diseases)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Digestive Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2833327</comments>
            <pubDate>Wed, 23 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2833327</guid>        </item>
        <item>
            <title>Treatment of Ulcerative Colitis in the Elderly</title>
            <link>http://www.medworm.com/index.php?rid=2833328&amp;cid=c_1_17_f&amp;fid=33521&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D228569</link>
            <description>Dig Dis 2009;27:327-334 (DOI:10.1159/000228569) (Source: Digestive Diseases)</description>
            <author>Digestive Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2833328</comments>
            <pubDate>Wed, 23 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2833328</guid>        </item>
        <item>
            <title>Severe Acute Ulcerative Colitis: The Pediatric Perspective</title>
            <link>http://www.medworm.com/index.php?rid=2833329&amp;cid=c_1_17_f&amp;fid=33521&amp;url=http%3A%2F%2Fcontent.karger.com%2Fproduktedb%2Fprodukte.asp%3Fdoi%3D228568</link>
            <description>Dig Dis 2009;27:322-326 (DOI:10.1159/000228568) (Source: Digestive Diseases)</description>
            <author>Digestive Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2833329</comments>
            <pubDate>Wed, 23 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2833329</guid>        </item>
        <item>
            <title>Mapping of inflammatory bowel disease in northern France: Spatial variations and relation to affluence</title>
            <link>http://www.medworm.com/index.php?rid=2822041&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21111</link>
            <description>Geographic variations in the incidence of inflammatory bowel disease (IBD) may reflect variations in the distribution of environmental etiologic factors. We assessed spatial variation in the incidence of IBD in northern France and analyzed its association with a deprivation index.All cases of IBD included in the EPIMAD registry between 1990 and 2003 were extracted. The standardized incidence ratio (SIR) was calculated for each canton in the region. The association between incidence and deprivation was assessed using the Townsend deprivation index.The mean annual incidence rates of Crohn's disease (CD) and ulcerative colitis (UC) were 6.2 × 10-5 and 3.8 × 10-5, respectively. The mean cumulative numbers of cases by canton were 18.4 (1-183) for CD and 11.3 (0-148) for UC. For both CD and UC...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2822041</comments>
            <pubDate>Tue, 22 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2822041</guid>        </item>
        <item>
            <title>Protective Effects of Selenium and Vitamin E Combination on Experimental Colitis in Blood Plasma and Colon of Rats.</title>
            <link>http://www.medworm.com/index.php?rid=2829028&amp;cid=c_1_62_f&amp;fid=37599&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19774348%26dopt%3DAbstract</link>
            <description>This study was carried out on three groups, namely the first (control), the second (experimental colitis group, 2 ml 5% acetic acid), and the third groups (2 ml 5% acetic acid, vitamin E (100 mg/kg body weight (bw)) plus Se (0.2 mg/kg bw)). The activities of catalase (CAT), prolidase (PRS), myeloperoxidase (MPO), total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI), total thiol (T-SH) were determined in plasma and colon samples. Macroscopic and microscopic damages in colon were increased by AA treatment (p &amp;lt; 0.01 and p &amp;lt; 0.01, respectively), whereas they were decreased by selenium and vitamin E treatment (p &amp;lt; 0.05 and p &amp;lt; 0.01, respectively). The activities of CAT and PRS in the plasma and colon were significantly affected (p &amp;lt; 0.05 and ...</description>
            <author>Biological Trace Element Research</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2829028</comments>
            <pubDate>Tue, 22 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2829028</guid>        </item>
        <item>
            <title>CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune system</title>
            <link>http://www.medworm.com/index.php?rid=2822044&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21106</link>
            <description>Inflammatory bowel disease (IBD) is characterized by increased lymphocytic infiltrate to the lamina propria (LP) and upregulation of inflammatory chemokines and receptors. CXCL12 is a constitutive chemokine involved in lung, brain, and joint inflammation. We hypothesized that CXCL12 and its receptor, CXCR4, would have a constitutive and inflammatory role in the gut.Intestinal epithelial cells (IECs) and T lymphocytes were isolated from intestinal mucosa of IBD and control patients undergoing bowel resection. Autologous T cells were isolated from peripheral blood (PB). CXCL12 and CXCR4 expression by IECs was assessed by polymerase chain reaction and immunohistochemistry, lymphocyte phenotype by flow cytometry, and migration by Transwells.IECs expressed CXCL12 and expression was increased an...&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2822044</comments>
            <pubDate>Mon, 21 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2822044</guid>        </item>
        <item>
            <title>Does psychological counseling alter the natural history of inflammatory bowel disease?</title>
            <link>http://www.medworm.com/index.php?rid=2822045&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21098</link>
            <description>There is increasing evidence that psychological stress can increase mucosal inflammation and worsen the course of inflammatory bowel disease (IBD). We have now assessed whether psychotherapy by a counselor specially trained in the management of IBD can influence the course of disease.Using retrospective case note review, we compared the course of IBD in 24 patients (13 ulcerative colitis; 11 Crohn's disease), during the year before (year 1) and the year after referral (year 2) for supportive outpatient psychotherapy to an IBD counselor, to that of 24 IBD controls who were matched to individual cases for age, sex, disease, duration of disease, medication at baseline, and for relapse rate in year 1. Counselor assessments were made using a visual analog scale 0-6 (0 denotes poor, 6 excellent ...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2822045</comments>
            <pubDate>Mon, 21 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2822045</guid>        </item>
        <item>
            <title>TLR5 is not required for flagellin-mediated exacerbation of DSS colitis</title>
            <link>http://www.medworm.com/index.php?rid=2822046&amp;cid=c_1_17_f&amp;fid=36804&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1002%252Fibd.21097</link>
            <description>The two forms of human inflammatory bowel disease, Crohn's disease (CD) and ulcerative colitis (UC), are both associated with loss of tolerance to gut microbial antigens. The dominant antigen recognized by antibody and T-cell responses in patients with CD is bacterial flagellin. Flagellin is also the only known ligand for Toll-like receptor 5 (TLR5), a key protein in innate immunity. Although flagellin activates TLR5 to produce inflammatory responses in many cell types in the gut, there is conflicting evidence as to whether TLR5 is harmful or protective in CD and murine colitis models. A recent study found that administration of flagellin enemas to mice along with dextran sodium sulfate (DSS) made their colitis worse.We sought to determine whether this exacerbation was due to TLR5 ligation...</description>
            <author>Inflammatory Bowel Diseases</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2822046</comments>
            <pubDate>Mon, 21 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2822046</guid>        </item>
        <item>
            <title>Crohn’s &amp; Colitis Foundation Encourages More Virtual Event Participants: Thousands Already Helped Foundation Raise Funds for Research &amp; Support Legislation</title>
            <link>http://www.medworm.com/index.php?rid=2813638&amp;cid=c_1_34_f&amp;fid=22564&amp;url=http%3A%2F%2Fwww.prweb.com%2Freleases%2Fccfamarchonthehill%2F2009%2Fprweb2907604.htm</link>
            <description>The Crohn&amp;#8217;s &amp;#38; Colitis Foundation and Shire plc (LSE: SHP, NASDAQ: SHPGY) today announced that more than 6,800 Facebook&amp;#174; users have participated in its first-ever virtual &amp;#8220;Inflammatory Bowel Disease (IBD) March on the Hill&amp;#8221; at www.ibdmarchonthehill.com. Using social media tools, the program aims to promote awareness about and raise funds for research and programs supporting those battling Crohn&amp;#8217;s disease and ulcerative colitis, chronic and painful digestive diseases impacting more than 1.4 million Americans. Website visitors are asked to show their support by selecting a unique shoe to place on the virtual &amp;#8220;Hill&amp;#8221; and are able to see how their step has impacted the total number of steps taken to date. (PRWeb Sep 21, 2009)
    Read the full story a...</description>
            <author>PRWeb:  Medical  Pharmaceuticals</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2813638</comments>
            <pubDate>Mon, 21 Sep 2009 17:08:25 +0100</pubDate>
            <guid isPermaLink="false">2813638</guid>        </item>
        <item>
            <title>Vitamin D receptor genotype may influence UC patient bone density</title>
            <link>http://www.medworm.com/index.php?rid=2813368&amp;cid=c_1_17_f&amp;fid=36313&amp;url=http%3A%2F%2Fwww.medwire-news.md%2F41%2F84420%2FGastroenterology%2FVitamin_D_receptor_genotype_may_influence_UC_patient_bone_density_.html</link>
            <description>Variants in the vitamin D receptor gene are associated with bone mineral density in people with ulcerative colitis, study results indicate. (Source: MedWire News - Gastroenterology)</description>
            <author>MedWire News - Gastroenterology</author>
            <type>news</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2813368</comments>
            <pubDate>Mon, 21 Sep 2009 16:33:14 +0100</pubDate>
            <guid isPermaLink="false">2813368</guid>        </item>
        <item>
            <title>5-ASA in ulcerative colitis: Improving treatment compliance.</title>
            <link>http://www.medworm.com/index.php?rid=2812629&amp;cid=c_1_17_f&amp;fid=37909&amp;url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19764084%26dopt%3DAbstract</link>
            <description>In conclusion, at present, 5-ASA MMx seems theoretically the best agent for maintaining patient compliance, and consequently, treatment effectiveness.
    PMID: 19764084 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)&lt;div id=&quot;medworm&quot;&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;MedWorm Message:&lt;/i&gt;&lt;/b&gt; Get the very latest Swine Flu news via the MedWorm &lt;b&gt;&lt;a href=&quot;http://www.medworm.com/rss/search.php?qu=%2Bswine+%2B%28influenza+flu%29&amp;t=Swine+Flu&amp;f=infectiousdiseases&amp;r=Any&amp;o=d&quot; target =&quot;_self&quot;&gt;Swine Flu RSS news feed&lt;/a&gt;&lt;/b&gt; -  updated hourly from thousands of authoritative health and news sources.&lt;/p&gt;&lt;/div&gt;</description>
            <author>World Journal of Gastroenterology : WJG</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2812629</comments>
            <pubDate>Sun, 20 Sep 2009 21:31:03 +0100</pubDate>
            <guid isPermaLink="false">2812629</guid>        </item>
        <item>
            <title>Predsol (prednisolone sodium phosphate) Retention Enema - Revised SPC</title>
            <link>http://www.medworm.com/index.php?rid=2810955&amp;cid=c_1_17_f&amp;fid=38903&amp;url=http%3A%2F%2Fwww.nelm.nhs.uk%2Fen%2FNeLM-Area%2FOther-Lib-Updates%2FSPC-Changes%2FPredsol-prednisolone-sodium-phosphate-Retention-Enema---Revised-SPC%2F</link>
            <description>Source: eMC (electronic Medicines Compendium)
Area: Other Library Updates &gt; SPC Changes
 Section 4.4 (special warnings and precautions for use) has been updated with the warning to use with caution in patients with myasthenia gravis, non-specific ulcerative colitis, diverticulitis and&amp;nbsp;fresh intestinal anastamoses. 
 Section 4.5 (interactions) has been updated to&amp;nbsp;include interactions with fluoroquinolones, anticholinesterases, licorice and neuromuscular blockers. 
 Ssection 4.8 (undesirable effects)&amp;nbsp;has been updated to include blood and lymphatic system disorders - alteration in lipid levels, leukemoid reactions; ophthalmic - chorioretinopathy; dermatological - dermatitis and toxic epidermal necrolysis. (Source: NeLM - Gastroenterology)</description>
            <author>NeLM - Gastroenterology</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810955</comments>
            <pubDate>Sat, 19 Sep 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2810955</guid>        </item>
        <item>
            <title>Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates</title>
            <link>http://www.medworm.com/index.php?rid=2808730&amp;cid=c_1_17_f&amp;fid=37078&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FGLDSCupdatesibd%2F%7E3%2FO2BIW7b_XjE%2FviewResource.aspx</link>
            <description>Published September 2009Bottom-line conclusion: If 5-Aminosalicylates (5-ASA) are efficacious chemoprevention for ulcerative colitis (UC)-associated colorectal cancer (CRC), endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional quality-adjusted life-year (QALY) gained. (Source: Gastroenterology and Liver Diseases Specialist Library - Inflammatory bowel disease)</description>
            <author>Gastroenterology and  Liver Diseases Specialist Library - Inflammatory bowel disease</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2808730</comments>
            <pubDate>Sat, 19 Sep 2009 16:25:58 +0100</pubDate>
            <guid isPermaLink="false">2808730</guid>        </item>
        <item>
            <title>Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates</title>
            <link>http://www.medworm.com/index.php?rid=2808732&amp;cid=c_1_17_f&amp;fid=37083&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FGLDSCupdatesprevention%2F%7E3%2FO2BIW7b_XjE%2FviewResource.aspx</link>
            <description>Published September 2009Bottom-line conclusion: If 5-Aminosalicylates (5-ASA) are efficacious chemoprevention for ulcerative colitis (UC)-associated colorectal cancer (CRC), endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional quality-adjusted life-year (QALY) gained. (Source: Gastroenterology and Liver Diseases Specialist Library - Prevention)</description>
            <author>Gastroenterology and  Liver Diseases Specialist Library - Prevention</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2808732</comments>
            <pubDate>Sat, 19 Sep 2009 16:25:46 +0100</pubDate>
            <guid isPermaLink="false">2808732</guid>        </item>
        <item>
            <title>Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates</title>
            <link>http://www.medworm.com/index.php?rid=2808729&amp;cid=c_1_17_f&amp;fid=37077&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FGLDSCupdatescolrect%2F%7E3%2FO2BIW7b_XjE%2FviewResource.aspx</link>
            <description>Published September 2009Bottom-line conclusion: If 5-Aminosalicylates (5-ASA) are efficacious chemoprevention for ulcerative colitis (UC)-associated colorectal cancer (CRC), endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional quality-adjusted life-year (QALY) gained. (Source: Gastroenterology and Liver Diseases Specialist Library - Colon and rectum)</description>
            <author>Gastroenterology and  Liver Diseases Specialist Library - Colon and rectum</author>
            <type>organizations</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2808729</comments>
            <pubDate>Sat, 19 Sep 2009 16:15:22 +0100</pubDate>
            <guid isPermaLink="false">2808729</guid>        </item>
    </channel>
</rss>
